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Chapter 1 
 
General Introduction 
 
1.1. Actinomycetes 
Actinomycetes are a large group of phylogenetically related, filamentous, aerobic Gram-
positive bacteria that show high GC-content in their genetic materials. The actinomycetes 
typically have two features. The first is a complex life cycle of morphological differentiation 
including the germination of spores, the elongation and branching of substrate mycelia, the 
formation of aerial mycelia, the septation of hyphae, and spore maturation (Chater and Losick 
1997). The second feature is that actinomycetes are prolific sources of bioactive compound 
production. Among the bioactive compounds derived from microbial sources, actinomycetes 
produce over 10,000 compounds, representing the largest group (45%) of bioactive microbial 
metabolites (Lazzarini et al. 2001) (Table 1). 
 
Table 1.1. Approximate numbers of bioactive microbial natural products (2002) 
Source Antibiotic Other bioactive 
metabolites 
Total bioactive 
metabolites (%) 
Practically 
used 
Actinomycetes 8,700 1,400 10,100 (45%) 100–120 
Bacteria 2,900 900 3,800 (17%) 10–12 
Fungi 4,900 3,700 8,600 (38%) 30–35 
Total 16,500 6,000 22,500 (100%) 140–160 
 
Of the known bioactive metabolites that are used directly in human and veterinary 
medicine and agriculture, most are derived from actinomycetes, and of the approximately 
10,000 bioactive compounds produced by actinomycetes, 7,600 (74%) are produced by 
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Streptomyces. The sources of the other approximately 2,500 (26%) bioactive compounds are 
called rare actinomycetes or non-Streptomyces producers. In the group of rare actinomycetes, 
Micromonospora, Actinomodura and Nocardia are the most frequent producers; each genus 
produces several hundred bioactive compounds (Raja and Prabakarana 2011) (Table 1.2). 
 
Table 1.2. Numbers of microbial metabolites produced by actinomycetes 
Actinomycetales species No.  
Streptomyces 8,000 
Micromonospora 740 
Nocardia 357 
Actinomadura 345 
Streptoverticillium 258 
Actinoplanes 248 
Saccharopolyspora 131 
Amycolatopsis 120 
Streptosporangium 79 
Mycobacterium 57 
Other 665 
Total 11,000 
 
Rare actinomycetes produce the most diverse and most unique compounds, displaying 
excellent antibacterial activities and usually low toxicity. They produce some important 
compounds such as gentamicins, erythromycins, vancomycin and rifamycin. Among the rare 
actinomycetes, Micromonospora has been recognized as a significant microorganism that 
produces bioactive compounds second only to Streptomyces (Berdy 2005). 
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1.1.1. Micromonospora 
The genus Micromonospora is Gram-positive, chemo-organotrophic and aerobic and has 
a high GC content like the rest of the actinomycetes. Micromonospora display a complex life 
cycle, differentiating into both substrate mycelia and spores, but they do not produce aerial 
mycelia. Micromonospora produce branched septate hyphae, and their colonies can be a variety 
of colors including white, orange, red and brown; sometimes the pigment may diffuse into the 
medium. When sporulation occurs, the single asexual spores of all Micromonospora species 
have spiny projections, and spores are formed on both short- and long-side branches (Vorbis 
1992). 
Micromonospora species are widely spread throughout nature, found in environments 
such as coastal sediments, marine sediment and plant rhizospears. Some species are known to 
form an intimate association with plants and are called endophytic Micromonospora (Hirsch 
and Valdés 2010). 
Micromonospora species are prolific sources of various bioactive metabolites. Over 700 
metabolites have been described from this genus (Table 1.2). They are well known for 
producing antibiotics, especially aminoglycosides, enediynes and oligosaccharides. The 
aminoglycosides, such as the gentamicins, are produced by M. purpurea and M. echinospora; 
sisomicin is produced from M. inyonensis and fortimicin from M. olivoasterospora. The 
macrolides compounds include rosamicin from M. rosaria and the mycinamicins, isolated from 
M. griseorubida. A family of macrolides closely related to lipiarmycin, the clostomicins, is 
produced by M. echinospora. Rifamycin (of the ansamycins family) is isolated from 
M. halophytica. The polysaccharide everninomycin is a typical product of M. carbonacea 
(Tiwari and Gupta 2012). 
Micromonospora species have been reported to have the important roles in soil ecology 
such as biodegradation, bio-control and plant growth-promoting hormones (Hirsch and Valdés 
2010). The versatile abilities of Micromonospora indicate that this genus is an important strain 
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for further study and development. 
 
1.2. Secondary metabolites 
“Natural products” are commonly defined as the chemical compounds isolated from 
various living things. These compounds may be derived from the primary or secondary 
metabolism of living organisms. The primary metabolites are normally found in all organisms. 
The secondary metabolites derived from microorganism and fungi are mostly low-molecular-
weight (< 3,000 kDa) and comprise widely differing chemical compounds with unclear 
functions. The secondary metabolites studied to date display a variety of functions; some 
present as antibiotics with antimicrobial, antitumor and antiviral activities, and some exhibit 
activity as a growth regulator, modifying the replication and inhibition of the life cycle of 
prokaryotic or eukaryotic cells at the biochemical level (Berdy 2005). 
Secondary metabolites are categorized into five main groups based on their core 
component, which provides the main structure of the compound (Turner and Aldridge 1984). 
1. Carbohydrate from saccharide 
2. Isoprenoid (or terpenoid) from isopentenyl diphosphate (IPP) 
3. Aromatic amino acid from shikimic acid 
4. Nonribosomal peptide from amino acid 
5. Polyketide from malonyl coenzyme A 
 
1.2.1. Carbohydrates 
Carbohydrates are the most common components of plants, animals and microorganisms. 
The compounds in the carbohydrate family have a variety of functions. For example, the 
polysaccharide compound glycogen serves as a mammalian carbohydrate storage molecule 
(Paul 2009), and chitosan is an important industrial material used for water purification (Kumar 
et al. 2004). 
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Aminoglycosides form a valuable group of antibiotics and are notably recognizable as 
modified carbohydrate molecules. They have two or three uncommon sugars, mainly 
aminosugars, with glycoside linkages tethered to an aminocyclitol such as an amino-substitute 
cyclohexene system, which also has a carbohydrate origin (Magnet and Blanchard 2005). An 
example of an aminoglycoside is gentamicin (Fig. 1.1), which is the clinically most important 
of the aminoglycoside antibiotics, broadly used for the treatment of serious infections. 
Gentamicin has broad-spectrum activity against pathogenic enterobacteria (Unwin et al. 2004). 
A second example is neomycin (Fig. 1.1), which shows activity against Gram-positive 
and Gram-negative bacteria. It is used for the oral treatment of intestinal infections and has 
applications in eye drops, ear drops and ointments (Huang et al. 2005). 
 
Fig. 1.1. The aminoglycoside antibiotics gentamicin and neomycin B. 
 
1.2.2. Isoprenoids 
Isoprenoids form a large and structurally diverse family of natural products derived from 
a C5 isoprene unit joined in a head-to-tail fashion (Sacchettini and Poulter 1997). Isoprenoids 
and their derivatives play key roles in all aspects of life such as in reproductive hormones 
(steroids, gibberellins and abscisic acid), as components of the cell membrane (steroids), in 
respiration (quinones), as photosynthetic light-harvesting compounds (carotenoids), and in 
protein targeting and regulation (prenylation). In addition, particularly in plants, isoprenoids 
play diverse roles other than maintenance of the life cycle, including roles in protection, 
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communication, pollination attraction and plant dispersion and as a constituent of essential oils 
such as -demascenone in rose, limonene in citrus and zingiberene in ginger (Chan and 
Keasling 2006). Typical examples of isoprenoids are shown in Figure 1.2. 
 
 
Fig. 1.2. Isoprenoids in nature: limoene, abscisic acid, and paxilline. 
 
1.2.3. Aromatic amino acids 
The aromatic amino acids such as L-phenylalanine, L-tyrosine and L-tryptophan are 
typically synthesized via the shikimate pathway (Paul 2009). A central intermediate in the 
pathway is shikimic acid (Fig 1.3), a compound isolated from plants. Shikimic acid is currently 
used as the raw material for the synthesis of the antiviral drug osetamivir (Tamiflu) against 
avian influenza (Farina and Brown 2006). Phenylalanine and tyrosine are found in many natural 
products such as cinnamic acid, coumarins and flavonoids, along with the tryptophan precursor 
of a wide range of alkaloid structures (Knaggs 2003). The compounds in this group, such as 
chloramphenicol, display a broad spectrum of antibiotic activity and are synthesized via the 
shikimate pathway (He et al. 2001) as shown in Figure 1.3. 
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Fig. 1.3. Chloramphenicol synthesis via the shikimate pathway 
 
1.2.4. Nonribosomal peptides 
Nonribosomal peptides are a class of peptide secondary metabolites with pharmacological 
importance. They have a wide range of uses including applications as antibiotics, 
immunosuppressive agents, cytostatic agents and siderophores  (Sieber and Marahiel 2005). 
The structures of some nonribosomal peptide compounds are shown in Figure 1.4. 
Nonribosomal peptides contain a number of structural features that clearly separate them 
from ribosomal peptide compounds. For example, they contain non-proteinogenic amino acids 
such as ornithine in gramicidins, and hydroxyphenyl or dihydroxyphenyl-glycine in 
vancomycin (Schwarzer et al. 2003). 
 
Fig. 1.4. Examples of nonribosomal peptide compounds. 
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Nonribosomal peptide compounds are synthesized through nonribosomal peptide 
synthetases (NRPSs). NRPSs are modularly organized multi-enzyme complexes, which display 
the extraordinary size and show the same time template and biosynthetic machinery (Schwarzer 
et al. 2003). 
 
1.2.5. Polyketides 
Polyketides are natural compounds containing alternating carbonyl and methylene group 
(-polyketones)  
Polyketides are an important group of secondary metabolites, display an incredible variety 
of functional and structural diversity with important activities including antimicrobial, 
anticancer, antifungal, antiparasitic and immunosuppressive activities (Staunton and Weissman 
2001). Examples of polyketide compounds are shown in Figure 1.5. 
Polyketides are synthesized through sequential reactions catalyzed by polyketide 
synthases (PKSs), which exert a series of enzymatic activities. 
 
Fig. 1.5. Examples of polyketide compounds: erythromycin A, actinorhodin, and rapamycin. 
 
1.2.5.1. Polyketide synthases 
The process of synthesizing polyketide synthases (PKSs) is generally similar to fatty acid 
biosynthesis, in which the growing chain is constructed by a Claisen reaction and catalyzed by 
ketosynthase activity. In fatty acid biosynthesis, the reaction initially produces a -ketoester, 
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and the ketone group is reduced after a condensation step and before the next round of chain 
extension. The overall reduction is achieved by a three-stage process: reduction to an alcohol 
by ketoreductase (KR), dehydration to the conjugated ester by dehydratase (DH), and reduction 
of the double bond by enoyl-reductase (ER) (Staunton and Weissman 2001). These reactions 
are illustrated in Figure 1.6. 
 
Fig. 1.6. Mechanisms underlying the biosynthesis of polyketide synthases. 
 
In fatty acid biosynthesis, all keto groups will be reduced by the three-step process of 
reduction and dehydration as mentioned above. However, the biosynthesis of PKSs differs from 
fatty acid biosynthesis because of varying degrees of reduction or dehydration. The polyketide 
assembly line may contain a mixture of hydroxyl groups, carbonyl groups, double bonds and 
methylene groups. This means that the enzyme activities KR, DH and ER are not active during 
the specific extension cycles. The order in which the modifications occur or do not occur is 
closely controlled by the enzyme activities (Paul 2009). Finally, the condensation cycles 
continue until reach the proper chain length, then the action of thioesterase (TE) domain will 
take place and release the acyl chain from the ACP to yield premature polyketide compound 
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(Moss et al. 2004). 
PKSs are classified into three groups according to their sequences, primary structure and 
catalytic mechanisms (Shen 2003), as follows. 
(1) Type I PKSs: Very large multifunctional proteins with individual functional 
domains. Type I PKSs can either be modular or iteratively modular, usually when 
present in a bacterial or fungal system, respectively. 
(2) Type II PKSs: Composed of a complex of individual monofunctional proteins; 
usually referring to the aromatic polyketide compounds. 
(3) Type III PKSs: Homodimeric enzymes that essentially are iteratively condensing 
enzymes, type III PKSs are sometimes described as being involved in chalcone 
biosynthesis. 
This dissertation will focus on modular type I PKSs. 
 
1.2.5.2. Modular type I PKSs 
Modular type I PKSs are large multifunctional polypeptides that are responsible for the 
biosynthesis of complex macrolides such as erythromycin and rapamycin. For typical modular 
PKSs, each module contains the essential domains ketosynthase (KS), acyltransferase (AT) and 
acyl carrier protein (ACP) for polyketide chain extension and the optional reductive domains 
ketoreductase (KR), dehydratase (DH) and enoyl reductase (ER) for reductively process -keto 
ester. (Tian et al. 2015) 
 In modular type I PKSs, each successive chain extension cycle is catalyzed by various 
sets of domains located in different modules; one or more modules may be present on one 
multifunctional polypeptide, and each domain is used only once (Moss et al. 2004). An example 
is the biosynthesis of 6-deoxyerythronolide B (6-dEB), in which PKSs catalyze the 
decarboxylation condensation of six methyl malonyl-CoA extender units with a propionate 
starter unit derived from propionyl CoA. The 6-dEB synthase (DEBS) consists of three 
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multifunctional proteins (DEBS1, DEBS2 and DEBS3), and each gene harbors two extension 
modules. This linear mechanism appears to be common among modular PKSs in bacterial 
systems (Fig 1.7). 
  
Fig. 1.7. The co-linear and nature of modular type I PKSs: The biosynthesis of 6-dEB by DEBS1, 
DEBS2 and DEBS3. 
 
Modular type I PKS systems have been acknowledged as a potential system to be 
engineered and to generate novel analogues of known metabolites. Combinatorial biosynthesis 
techniques such as gene deletion or the gene modification of post-PKS tailoring in modular 
Type I PKSs are among the alternative ways to create new derivatives of polyketide compounds. 
 
1.2.5.3. Post-PKSs tailoring step 
After a PKS has been synthesized, post-PKS modification is an essential step to modify 
the polyketide framework. A modification such as the introduction of a hydroxy group or 
methyl group or glycosyl transfer can particularly change the therapeutic index of the parent 
polyketides, or alter some impact factors such as physio-properties, changing the solubility or 
the receptor binding ability of the modified parent compound (Rix et al. 2002). Figure 1.8 
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describes the post-PKS modification of erythromycin A. 
 
 
Fig. 1.8. Post-PKS modification of erythromycin A. 
 
The post-PKS modification enzymes have play the important roles in natural products 
biosynthesis, among those enzymes, the cytochrome P450 monooxygenases (CYP450s) are 
well-known to be involved in regiospecific and stereospecific oxidation of polyketide 
compounds (Lamb et al. 2013). The studies on the modification of CYP450s have been attracted 
great attention for generation of novel polyketide derivatives. 
 For example, the study on fscP gene encoding CYP450 monooxygenase of candicidin 
biosynthesis by gene disruption on Streptomyces sp. strain FR-008 showed that fscP mutant 
strain produced the new derivative of candicidin, decarboxylated candicidin (Fig. 1.9). However, 
the new derivative displayed lower antifungal activity than in candicidin (Chen et al. 2009).  
 
 
Fig. 1.9. The disruption of fscP gene in candicidin biosynthesis 
 
 
 
13 
 
1.2.5.6. Polyketide-class compounds 
Several groups of compounds are categorized as polyketide-class compounds because 
their main structure is synthesized via a PKS pathway. The groups of compounds including 
macrolide antibiotics, polyene antibiotics, ansamycin antibiotics and the recently growing 
spirotetronate compound family are explained as follows. 
Macrolide antibiotics are macrocyclic lactones typically composed of 12–16 ring-sized 
atoms, with some branching through methyl substituents. Two or more sugar units are attached 
through glycoside linkage, such as L-mycarose, D-mycinose and L-oleandrose. At least one 
sugar is an amino sugar; for example, D-desosamine, D-forosamine and D-mycaminose. The 
compounds in this group have a narrow spectrum of antibacterial activity especially against 
Gram-positive bacteria (Pal 2006). Examples of this group are erythromycin A (Fig. 1.5) and 
tylosin (Fig. 1.9). 
Polyene antifungals are a group of macrocyclic lactones with very large (26–38)-member 
rings. They are categorized by the existence of a series of conjugated E-double bonds and are 
classified according to the presence of the longest conjugated chain. The polyene antifungals 
have no antibacterial activity, but they are promising as antifungal agents (Aparicio et al. 2004). 
The polyene compounds amphotericin B and nystatin are shown in Figure 1.9. 
Ansamycin antibiotics are macrolides that have non-adjacent positions on an aromatic 
ring bridged by a long aliphatic chain. The aromatic portion may be replaced by naphlaene or 
naphthaquinone, or a benzene ring. The macrocycle in the ansamycins is closed by an amide 
rather than ester linkage. An example of this group is rifamycin (Fig 1.9), which is the only 
ansamycin currently used clinically (Floss and Yu 2005). 
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Fig. 1.9. Polyketide-class compounds. 
1.3. Tetronate compounds 
Tetronate compounds are a group of natural products that show great structural and 
functional diversity. The structure of this group consists of a linear fatty acid or polyketide 
backbone, tethered with a tetronic acid ring system (4-hydroxy-[5H] furan-2-one, Fig. 1.10). 
Several tetronate compounds have been reported, and the compounds can be classified 
according to distinct structural features such as linearity or the macrocyclization of the carbon 
backbone and the size of the central ring system (Vieweg et al. 2014). There are two types of 
tetronate compounds: linear tetronates and spirotetronates. 
 
Fig. 1.10. Tetronic acid tautomer. 
 
1.3.1. Linear tetronates 
The linear tetronate compounds are characterized by the lack of macrocyclization of a 
linear carbon backbone attached to a tetronic acid moiety, although the occurrence of small- 
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and medium-sized rings within the molecule is accepted. Figure 1.11 shows examples of linear 
tetronates. 
 
Fig. 1.11. The linear tetronates agglomerins and RK-682. 
 
Agglomerin A and its derivatives B–D were isolated from Pantoea agglomerans PB-6024  
(Shoji et al. 1989). The agglomerins consist of -acyl-chains that are derived from primary fatty 
acid metabolism and a tetronic acid bearing an exocyclic double bond (Kanchanabanca et al. 
2013). These compounds show activity against a range of anaerobic bacteria. Another linear -
acyl-chain tetronate compound is RK-682, which was isolated from Streptomyces sp. 88-682. 
This compound consists of a fatty acid tethered to a tetronic ring, which is decorated with a 
methyl-enehydroxy moiety instead of the exocyclic double bond that is present in agglomerins. 
RK-682 displays various activities and has been described as an inhibitor of the tyrosine 
phosphatases HIV-I protease and heparanase (Hamaguchi et al. 1995). 
 
1.3.2. Spirotetronates 
Spirotetronates are tetronate compounds in which tetronic acid spiro-links with 
cyclohexene ring sometimes conjugated with trans-decalin unit (Fig. 1.12). Several reports 
about spirotetronates support the hypothesis that all spirotetronate frameworks are synthesized 
according to a general mechanism involving polyketide assembly lines. It was suggested that 
the formation of a spirotetronate requires a conjugated pair of carbon-carbon double bonds in 
the tail region of the linear polyketide precursor plus a characteristic exocyclic double bond on 
the tetronic ring system. Spirotetronate compounds can be classified based on the size of the 
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central ring system and also the molecular weight, which is influenced mainly by the degree of 
glycosylation (Vieweg et al. 2014). Spirotetronates can be divided into three classes: small, 
medium and large spirotetronates. 
 
Fig. 1.12. The common structure of spirotetronates 
 
1.3.2.1. Small spirotetronates 
The small spirotetronates consist of macrocyclized tetronates with a polyketide 
backbone; they are low-molecular-weight and their central ring systems consist of 11 carbon 
atoms (Fig. 1.13). An example of a small spirotetronate is abyssomicin (Fig. 1.13). This 
compound has various derivatives that show anti-Gram-positive bacteria and anti-tuberculosis 
activities (Riedlingera et al. 2004). 
 
Fig. 1.13. A: central-ring system = C11. B: Abyssomicin B, a small spirotetronate. 
 
1.3.2.2. Medium spirotetronates 
The family of medium-sized spirotetronates represents the largest group of tetronates. The 
compounds in this group are comprised of a polyketide scaffold with six carbon linkers 
17 
 
connecting a cyclohexene ring and a decalin unit, constructing a 13-membered ring. The 
scaffold was found to be a polyketide-derived carbon backbone. The spirotetronate moiety and 
the trans-decalin unit are thought to arise from a Diels-Alder reaction taking place after the 
biosynthesis of the linear precursor molecule. The compounds in this medium-sized family 
display a variety of glycosylation patterns, given the large number of derivatives (Vieweg et al. 
2014). The best-studied spirotetronates in this family are chlorothricin, kijanimicin and 
tetrocarcin A (Fig. 1.14). 
 
Fig. 1.14. The medium-sized spirotetronates chlorothricin,kijanimicin and tetrocarcin A. 
 
Chlorothricin was isolated from Streptomyces antibioticus DSM 40725 and shows anti-
Gram-positive and cholesterol biosynthesis inhibitor activities (Kawashima et al. 1991). The 
biosynthesis of chlorothricin has been elucidated since 2006, when it was confirmed that the 
assembly machinery involves a large polyketide synthase complex (Jia et al. 2006). 
Kijanimicin was isolated from Actinomadura kijaniata SCC 1256 in 1981. It shows 
antibacterial activity, notably activity against Propionibacterium acne and Bacillus subtilis. 
This compound has an unusual nitrosugar called D-kijanose attached at the C-8 of the core 
structure and an L-digitose moiety attached at the decalin unit (Waitz et al. 1981). The 
biosynthetic gene cluster of this compound was isolated by Zhang et al and confirmed the 
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polyketide synthases are involved in construction of kijanimicin aglycone (Zhang et al. 2007). 
A third medium-sized spirotetronate, tetrocarcin A, was isolated from a culture of 
Micromonospora chalcea NRRL 11289. It displays antitumor activity. Tetrocarcin A is closely 
related to kijanimicin, but the decalin unit of tetrocarcin A includes a tetrasaccharide comprised 
of L-digitose and L-amitose (Tomita et al. 1980). The biosynthetic gene cluster of tetrocarcin A 
reveals that the gene cluster responsible for the production of tetrocarcin A is mainly from 
polyketide synthases such as chlorothricin and kijanimicin (Fang et al. 2008). 
 
 
1.3.2.3. Large spirotetronates 
This group contains various large-sized spirotetronates in which the central-ring system 
is larger than the 13-membered ring. Quatromicins and versipelostatin are examples of this 
group (Fig. 1.15).  
 
Fig. 1.15. The large spirotetronates quatromicin and versipelostatin. 
 
Quatromicins were isolated from Amycolatopsis orientalis, and they display a unique 
structure harboring four spirotetronate moieties within one molecule. Quatromicins exhibit 
antiviral activity against herpes simplex virus (Kusumi et al. 1991). 
With a 17-member ring, versipelostatin is the largest spirotetronate. It was first isolated 
from Streptomyces versipellis 4083-SVS6. It was found that versipelostatin downregurates of a 
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chaperon modulator (GRP78 chaperon protein) located in the endoplasmic reticulum (Park et 
al. 2002). 
To date, more than 60 tetronates and spirotetronates have been identified, and they have 
been recognized as having potential antibiotic, anticancer and antiviral applications. 
 
1.3.3. Maklamicin 
Maklamicin, isolated from the endophytic Micromonospora sp. NBRC 110955, displays 
strong to moderate antibacterial activity against Gram-positive bacteria and also cancer cell 
cytotoxicity (Igarashi et al. 2011) (Fig. 1.16). Maklamicin belongs to the small-sized 
spirotetronate family, which shows two structural features that are distinct from those of other 
spirotetronates as described below. 
 
Fig. 1.16. The structure of maklamicin 
 
1. The carbon chain linker of maklamicin is shortest in the spirotetronate family. 
Maklamicin has a four-carbon chain connection between its trans-decalin unit and 
cyclohexene ring, forming an 11-member ring, whereas the carbon chain length between the 
two ring systems in other spirotetronates such as chlorothricin and versipelostatin is 6 or 10, 
respectively, constructing a 13- or 17- member ring. 
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2. The stereogenic center at C-31 at the substituent on the cyclohexene ring has never been 
reported. 
Maklamicin contains a 2R-hydroxy-propyl group at C-21 as a substituent on the 
cyclohexene ring, creating a stereogenic center at C-31, whereas other spirotetronates have an 
achiral center substituent at the same position. Chlorothricin, compound AC6H, decatromicins 
and saccharocarcins have functional groups as a methyl, formyl ethyl and n-propyl groups, 
respectively (Fig. 1.17). 
 
 
Fig. 1.17. Spirotetronates with an achiral substituent on the cyclohexene ring. 
 
1.3.4. The biosynthesis of tetronates and spirotetronates 
Several studies of the biosynthesis of tetronates and spirotetronates have been reported. 
The elucidation of chlorothricin, kijanimicin and tetrocarcin A biosynthetic gene clusters (Fang 
et al. 2008; Jia et al. 2006; Zhang et al. 2007) revealed that the main spirotetronate scaffold is 
synthesized via linear type I PKSs. Two Diels-Alder reactions were postulated to build up the 
cyclohexene ring attached to the tetronate moiety and trans-decalin system. A study of 
kijanimicin biosynthesis revealed a set of five genes called glycerate utilization operons that 
are suspected to be responsible for the incorporation of the C3-unit from the glycolytic pathway 
for the formation of a tetronic acid moiety. However, there is no clear evidence to confirm the 
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function of the glycerate utilization operons. 
The biosynthesis of the tetronate compound agglomerin, which harbors a tetronate moiety 
with an exocyclic double bond, was elucidated in 2013 (Kanchanabanca et al. 2013). It was the 
first biosynthesis model that clearly provided a reasonable explanation of the formation of a 
tetronic acid moiety. The function of glycerate utilization operons has been clarified, indicating 
that this gene cassette is highly conserved in the biosynthesis of all tetronates and 
spirotetronates. 
1.3.4.1. Diels-Alder reactions 
The Diels-Alder reaction is a main reaction in organic synthesis for the formation of 
carbocycles through [4+2]-cycloaddition reaction in which a diene reacts with a dienophile to 
yield a cyclohexene ring in a concerted manner (Fig. 1.18)(Kasahara et al. 2010). The Diels-
Alder reaction is very useful in synthetic chemistry because of it has high region-
stereoselectivity. Moreover, various kind of natural products biosyntheses such as polyketides, 
terpenoid or alkaloid have been suggested that Diels-Alder reactions are involved in their 
biosynthesis (Oikawa and Tokiwano 2004). 
 
Fig. 1.18. The Diels-Alder reaction. 
 
Although the Diels-Alder reactions have been reported to be involved in the biosynthesis 
of several natural products but the reports about the genes that encoding Diels-Alderase are 
insufficient. The first Diel-Alderase gene, solanapyrone synthase (SPS) was reported in 1995 
on solanapyrone biosynthesis. Next, three additional Diels-Alderase, lovastatin nonakide 
synthase (LovB), macrophomate synthase (MPS) and spinosyn A (SpnF) biosynthesis were 
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reported and characterized their function (Oikawa and Tokiwano 2004).  
The general step of [4+2] cycloaddition reaction involved in the biosynthesis pathway of 
four natural products was showed in figure 1.19  
 
Fig. 1.19. Known [4+2] cycloaddition reactions 
 
Since the first report of chlorothricin biosynthesis on 2006, several spirotetronates 
biosynthesis have been elucidated but no enzyme has been shown to facilitate Diels-Alder 
reactions (Vieweg et al. 2014). Until January 2015, Hashimoto and his colleagues have 
successfully identified and characterized one gene, vstJ, which was demonstrated to be involved 
in the [4+2]-cycloaddition reaction of the formation of cyclohexene ring on versipelostatin 
biosynthesis. (Hashimoto et al. 2015). Moreover, on March 2015, Tian and his group also 
reported about the genes involved in Diels-Alder reactions on pyrroindomycins, the 
spirotetramate antibiotic which its structure related to spirotetronates. In this study revealed that 
two genes, pyrE3 and pyrI4, homologues of chlE3 and chlL in chlorothricin biosynthesis are 
involved in the formation of trans-decalin unit and cyclohexene ring, respectively (Fig. 1.20). 
The sequence of pyrE3 and pyrI4 does not share the sequence homology to each other (Tian et 
al. 2015).  
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Fig. 1.20. The Diels-Alderase involved in decalin unit formation and cyclohexene ring formation of 
spirotetronate compounds 
 
In general, the Diels- Alder reaction have been frequently used in the chemical synthesis 
of spirotetronate scaffold to assembly both decalin unit and cyclohexene ring system. Therefore, 
in the biosynthetic pathway, the decalin unit formation would undertake by an endo-selective 
Diels-Alder reaction whereas the cyclohexene ring formation would follow an exo-transition 
state. Moreover, all known type Diels-Alderase are phylogenetically difference, although the 
products share similar 6,6-bicyclic moiety (Tian et al. 2015). 
Interestingly, the homologues of dialkyl decalin synthase and spiro-conjugate synthase 
were found to be conserved in the biosynthesis of several spirotetronates. 
 
Based on the above-mentioned findings, a hypothesis regarding the biosynthesis of 
spirotetronates has been proposed in which the biosynthesis is based on the contribution of the 
following reactions. First, the assembly of linear type I polyketide compounds takes place. 
Second, the attachment of the tetronic acid moiety occurs, followed by a postulated Diels-Alder 
reaction to complete the macrocylization. Lastly, a tailoring modification such as hydroxylation 
or glycosylation modifies the core structure and may thus lead to the structural differentiation 
of spirotetronates (Vieweg et al. 2014) 
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1.4. Overview and objectives of this study 
As described above, the spirotetronate polyketide antibiotic maklamicin has two 
structural features that are unique from those of other spirotetronates. This inspired me to 
investigate the detail mechanisms underlying the unique structure of maklamicin at the 
molecular level. The objective of my study was to obtain genetic information about the 
biosynthesis of maklamicin, which was isolated from the endophytic actinomycetes 
Micromonospora sp. NBRC 110955. 
I began my investigation of maklamicin biosynthesis by conducting genome sequencing 
of Micromonospora sp. NBRC 110955, constructing the library, and performing a sequence 
analysis and gene disruption. As described in Chapter 2, the glycerate utilization operon 
involved in tetronate moiety formation was used as a probe for searching the genome database 
and for the screening of cosmid and Bacterial Artificial Chromosome (BAC) libraries. In 
addition, by chromosome walking and sequencing analyses, I identified the maklamicin gene 
cluster. Disruption of PKSs genes was performed to test the involvement of this gene cluster in 
maklamicin production. Lastly, I propose the pathway of maklamicin biosynthesis. 
Chapter 3 describes how the function of genes involved in the post-PKS modification of 
maklamicin biosynthesis was characterized by gene disruption and an in vivo resting cell assay. 
Moreover, a new maklamicin analogue was obtained from the culture of a cytochrome P450 
gene disruptant, and it displayed significant activities against Gram-positive bacteria. The 
general conclusions are given in Chapter 4. 
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Chapter 2 
 
Characterization of the biosynthetic gene cluster for maklamicin, a 
spirotetronate-class antibiotic of the endophytic  
Micromonospora sp. NBRC 110955 
 
2.1. Introduction 
The spirotetronate-class antibiotics are a growing family of polyketide natural products 
with a wide range of biological activities, including anti-bacterial, anti-tumor, and anti-viral 
activities (Vieweg et al. 2014). The compounds in this family possess a characteristic tetronate 
moiety spiro-linked to a cyclohexene ring, sometimes conjugated with a trans-decalin moiety. 
To date, almost 60 related spirotetronate antibiotics have been reported from actinomycetes, 
and can be classified into three subgroups based on the size of the central ring system and their 
molecular weight, with the latter mainly reflecting the glycosylation pattern. The largest and 
most homogenous group of spirotetronate antibiotics is the family of medium-sized 
spirotetronates, which comprises a 13-membered carbon macrocycle and several sugar moieties. 
An intriguing point of this group is that the spirotetronate moiety is connected to a trans-decalin 
system either by a carbonyl unit (for kijanimicin or tetrocarcin A) or by a carboxylic ester (for 
chlorothricin) (Kawashima et al. 1991; Takeda et al. 1991; Waitz et al. 1981). Although the 
trans-decalin system is also found in versipelostatin A, one of the large-sized spirotetronates 
comprising a central ring system larger than a 13-membered macrocycle (Park et al. 2002), 
most of the large-sized spirotetronates have no such trans-decalin system. The most 
representative of the small-sized spirotetronates consisting of the central 11-membered carbon 
ring system are the abyssomicins, which lack the trans-decalin system in their frameworks 
(Riedlingera et al. 2004). Several studies have revealed that the main framework of 
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spirotetronate antibiotics is biosynthesized by type I polyketide synthase (PKS) machinery, 
which occasionally forms the trans-decalin system by a postulated Diels-Alder reaction (Fang 
et al. 2008; Jia et al. 2006; Zhang et al. 2007). Although the biosynthetic mechanisms of 
spirotetronates have been partially elucidated with respect to the formation of the carbon ring 
system as well as the trans-decalin system, the detailed mechanism causing the structural 
differences remains to be clarified.  
Maklamicin, which is produced by the recently isolated endophytic Micromonospora sp. 
NBRC 110955, belongs to the family of small-sized spirotetronates and shows anti-microbial 
activity against Gram-positive bacteria, especially Micrococcus luteus (Igarashi et al. 2011). 
Unlike the small-sized spirotetronate abyssomicins, maklamicin includes a trans-decalin 
system that is connected to a spirotetronate moiety by both a carbonyl group and a four-carbon 
chain linker. The 4-carbon chain linker of maklamicin is the shortest in the spirotetronates 
family, whose members usually have a 6- or 10-carbon chain linker composing a 13- or 17-
membered macrocyclic ring (Vieweg et al. 2014). Another unique structural feature of 
maklamicin is the presence of a 2R-hydroxy-propyl group at C-21. While other spirotetronates 
have an achiral substituent at the same position, only maklamicin contains a stereogenic center 
at the substituent on the cyclohexene ring. The structural novelty of maklamicin in the family 
of spirotetronate antibiotics has spurred us to elucidate the biosynthetic mechanism of 
maklamicin at the molecular level, which will contribute to the generation of new 
spirotetronates with potentially improved properties.  
 
2.2. Materials and Methods  
2.2.1. Bacterial strains, plasmids, and growth conditions 
Micromonospora sp. NBRC 110955 isolated from the root of Maklam Phueak (Abrus 
pulchellus Wall. Ex Thwaites subsp. pulchellus) collected in Thailand. Micromonospora sp. 
NBRC 110955 was grown at 30oC on ISP medium 2 (Becton, Dickinson and Company, Franklin 
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Lakes, NJ, USA). Escherichia coli DH5α was used for general DNA manipulation (Sambrook 
and Russell 2001), and the DNA methylation-deficient E. coli strain ET12567 containing 
pUZ8002 (Paget et al. 1999) was used for E. coli/Micromonospora conjugation. E. coli strains 
were grown in Luria-Bertani (LB) medium, with appropriate antibiotics when necessary. The 
plasmids used were SuperCos 1 (Agilent Technologies) and pKU503 (Komatsu et al. 2010) for 
construction of the cosmid and bacterial artificial chromosome (BAC) libraries for the 
Micromonospora sp. NBRC 110955 genome, respectively, and pIJ773 (Gust et al. 2003) for 
PCR amplification of the oriT-aac(3)IV cassette for gene disruption. Micromonospora sp. 
NBRC 110955 was cultivated in a test tube (15 by 160 mm) containing 5 ml of liquid ISP2 
medium (0.2% yeast extract, 1% malt extract and 0.2% glucose, pH 7.2). The test tube was 
incubated on a reciprocal shaker (160 spm) at 30oC for 5 days. An aliquot (700 μl) of the culture 
was then inoculated into 70 ml of liquid ISP2 medium in a 500 ml baffled flask on a rotary 
shaker (170 rpm), and mycelia were harvested after 36 h of cultivation at 30oC. The mycelia 
were washed, resuspended in fresh liquid ISP2 medium, and stored at -80oC until use as a seed 
culture. All the primers are listed in Table 2.1. 
2.2.2. Genome sequencing and bioinformatics analyses  
The seed culture of Micromonospora sp. NBRC 110955 was inoculated into 70 ml of 
liquid ISP2 medium in a 500 ml baffled flask, diluted to an OD600 of 0.05, and cultivated for 2 
days. The mycelium was harvested by centrifuge and three grams of wet cell were used for 
Genomic DNA extraction according to the protocol from molecular cloning. Ten microgram of 
pure Genomic DNA was submitted to the Genome Analysis Centre, Norwich Research Park, 
UK, using 454 DNA pyrosequencing technology. One-quarter of a run of 454 sequencing 
yielded 104 Mb of sequence data which gave 14x coverage of the genome and were assembled 
using Newbler assembly software to give 373 contigs with a mean length of 18,317 bp. The 
assembled contig sequences and the Genome Matcher software (Ohtsubo et al. 2008) were used 
to analyze the potential maklamicin biosynthetic gene in the genome. Annotation of open 
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reading frames (ORFs) and gene functions was performed manually by using the FramePlot 
4.0beta program (http://nocardia.nih.go.jp/fp4/), 2ndFind program 
(http://biosyn.nih.go.jp/2ndfind/), BLAST algorithm and PKS/NRPS analysis program 
(http://nrps.igs.umaryland.edu/nrps/). The nucleotide sequence data reported in this paper have 
been deposited in the DDBJ data bank under accession number LC021382. 
Table 2.1. Oligonucleotides used in this study 
Primer Sequence (5`-3`) 
For cosmid and BAC libraries screening 
makB1-Fw GACAGCTGCGCCAAGCACCTGGAC 
makB1-Re CATTTTCGGCATGACCTGTTCGAG 
makB5-Fw ATCGTCAGCGTCAAGGAGCAGTGG 
makB5-Re CGGCGGGATGATCTCGTCACG 
For construction of makA1 disruptant 
makA1-Fw ACTAGTGTGATCCGCATGAAGCATGACCACGACCCGGTCGTCCCGATTCCGGGGATCCG
TCGACC 
makA1-Re TCTAGAGTCGCTCACCGCGGCCGGCAGGTCGCCGGCGCCCGCCCGTGTAGGCTGGAGCT
GCTTC 
makA1-cFw TCAGGAACGGCTTTAACGACCGACAAG 
makA1-cRe AGATCGCGTCGACCTCCTCGGTGAGCA 
For construction of makA4 disruptant 
makA4-Fw AAGTGGGTCACGGCGGATCTGCACAAGACCCGCCAGCGGATTCCGGGGATCCGTCGACC 
makA4-Re CTCCGGGGCGTGCGTACGCAGCCACTCCTGGCTGAGCGTTGTAGGCTGGAGCTGCTTC 
makA4-cFw GACGTGCGCGAGCGGCTGGACGGCGCCAG 
makA4-cRe GTGTCGGTCATGAGGAACTCCCTGTCGGTT 
  
2.2.3. Construction and screening of cosmid and BAC libraries of genomic DNA 
For construction of the cosmid library, 400 g of genomic DNA of the Micromonospora 
sp. NBRC 110955 was partially digested with Sau3AI. The appropriated size of partially 
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digested DNA was checked by electrophoresis using 0.3% Agarose gel (Takara, Japan), the 
electrophoresis was ran for 24 hour with 20 volt to obtain the best DNA separation. Next, the 
target DNA size around 30-56 kb was excised from the gel then purified and dephosphorelated.  
Following, 2.5 g of 30-56 kb DNA fragments were ligated into XbaI-BamHI-digested of 1 g 
dephosphorylated SuperCos 1. Southern blot analysis was performed to confirm the ligation 
between DNA fragment and SuperCos 1. Next, E. coli XL-1 Blue MR and Gigapack III plus 
packaging extract (Agilent Technologies) were used for the library construction according to 
the manufacturer’s instructions. For construction of the BAC library, partially digested DNA 
fragments of 150 to 220 kb were purified, and cloned with a large BamHI segment of pKU503 
as described previously (Aroonsri et al. 2012; Komatsu et al. 2013). The cosmid library (1,100 
colonies) and BAC library (2,700 colonies) were screened by PCR using primers designed from 
the 454 sequence data. The primer are listed in table 2.1.  
 
2.2.4. Genetic disruption in the Micromonospora sp. NBRC 110955 
Disruptants in which the internal region of the makA1 and makA4 genes were deleted 
were constructed by λRED-mediated PCR-targeted mutagenesis (Gust et al. 2003). 
The approach of Red-mediated PCR targeted mutagenesis of Micromonospora sp. 
NBRC 110955 is to replace a chromosomal sequence within Micromonospora sp. NBRC 
110955 cosmid by apramycin marker that has been generated by PCR using primer with 39 
nucleotide homology with gene to be deleted (Fig. 2.1). The primers was designed by 5’ ends 
of primer is overlapping the regions of upstream and downstream of the mak coding region and 
3’ ends of primer designed to amplify the apramycin resistance oriT-aac(3)IV disruption 
cassette of pIJ773 (Fig 2.1) (Gust et al. 2003): makA1-Fw and makA1-Re for makA1 disruption; 
makA4-Fw and makA4-Re for makA4 disruption. The amplified DNA was introduced into the 
cosmid 1E1 for makA1 or the cosmid 10E6 for makA4 using λRED-mediated recombination 
with E. coli BW25113/pIJ790 (Gust et al. 2003). 
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Fig 2.1. Designing PCR primers for making in-frame deletion. The 59 and 58 nucleotides (nt) primers were 
designed by 39 nt of primers (5’) are overlapping with target regions upstream and downstream and 20 nt or 
19 nt (3’) primers are overlapping with apramycin cassette from pIJ773 plasmid.   
  
The procedure of Red-mediated PCR targeted mutagenesis was explained in Fig 2.2.  
 
 
Fig. 2.2. The principle of Red-mediated PCR mutagenesis in Micromonospora sp. NBRC 110955. (a) The 
amplification of apramycin (apr) cassette from pIJ773 by 59 and 58 nt primers according to fig 2.1. (b) The 
introduction of apramycin cassette to E. coli BW25113/pIJ790 ( RED recombination plasmid) harboring 
Micromonospora NBRC 110955 cosmid to obtain the cosmid with the target region was replaced by 
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apramycin cassette (mutant cosmid). (c) The mutant cosmid was transferred to E. coli ET12567/pUZ8002 
and conjugated with Micromonospora sp. NBRC 110955 (d) The target region in Micromonospora 
chromosome was replaced by apramycin cassette causing gene inactivation. 
  
The disrupted cosmids were transferred via E.coli ET12567/pUZ8002 to the 
Micromonospora sp. NBRC 110955 by intergeneric conjugation. An LB culture of the donor E. 
coli ET12567/pUZ8002 harboring the disrupted cosmid was grown to an optical density at 600 
nm (OD600) of 0.4-0.6. The cells harvested were washed twice with LB and resuspended in a 
0.1 volume of LB. The seed culture of the recipient Micromonospora sp. NBRC 110955 was 
inoculated into 70 ml of liquid ISP2 medium in a 500 ml baffled flask, diluted to an OD600 of 
0.05, and cultivated for 2 days. The harvested mycelia were washed twice with Tryptone Soya 
Broth (TSB; Oxoid, Basingstoke, UK), resuspended in a 0.1 volume of TSB, and then mixed 
with the E. coli donor cells in a ratio of 1:1 (v/v). After incubation at 25oC for 30 min, the 
mixture was spread on ISP medium 2 containing 30 mM MgCl2. After incubation at 28
oC for 
20 h, the plates were overlaid with water containing 1 mg of apramycin (Sigma, Japan) and 0.5 
mg of nalidixic acid (Wako, Japan) and the incubation was continued at 30oC. The genotype of 
candidates for disruption of the corresponding genes was confirmed by PCR analysis. The 
Micromonospora sp. NBRC 110955 makA1 and makA4 disruptants were abbreviated ΔmakA1 
and ΔmakA4, respectively.  
 
2.2.5. Analysis of maklamicin production 
The seed culture of Micromonospora sp. NBRC 110955 was cultivated in a 500 ml baffled 
flask containing 100 ml of V-22 medium (Igarashi et al. 2011). The baffled flask was incubated 
on a rotary shaker at 30oC for 4 days. An aliquot (3 ml) of the culture was then inoculated into 
100 ml of A11M medium (Igarashi et al. 2011) in a 500 ml baffled flask. After 6 days of 
cultivation, the culture broth was extracted with a half volume of n-butanol. After the organic 
layer was evaporated and dissolved with methanol, the crude extract was subjected to reversed-
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phase HPLC on a CAPCELL-PAK C18 column (UG80; 5 μm; 4.6 by 250 mm; Shiseido, Tokyo, 
Japan) developed with a gradient system of acetonitrile (75% for 0-5 min; 75% to 95% for 5-
25 min) containing 0.1% formic acid (flow rate, 1.2 ml/min; UV detection, 254 nm). Purified 
maklamicin was used as a standard for HPLC analysis.  
 
2.3. Results 
2.3.1. Cloning and identification of the maklamicin biosynthetic gene cluster  
To identify the maklamicin biosynthetic gene cluster, the genome of the Micromonospora 
sp. NBRC 110955 was sequenced using 454 pyrosequencing technology. 104 Mb of sequence 
data were obtained, resulting in a 14-fold read coverage, and the reads were assembled into 373 
contigs with an average length of 18,317 bp. The genome size is approximately 7.4 Mb. The 
chemical structure of maklamicin indicated that type I modular PKSs and tetronate-forming 
enzymes are involved in the biosynthesis of maklamicin. The study on biosynthesis of 
agglomerin A which is a tetronate antibiotic isolated from Pantoea agglomerans. Agglomerin 
A is not a spirotetronate antibiotic but has a tetronate moiety with an exocyclic double bond in 
the structure, revealed a set of proteins encoded by the “glycerate utilization operon” (agg1 to 
agg5) for biosynthesis of the tetronate moiety (Fig. 2.3) (Kanchanabanca et al. 2013). 
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Fig. 2.3. Presumed steps for formation of the tetronate moiety. 1,3-Bisphosphoglycerate is 
activated by loading onto a discrete ACP by the action of a glyceryl-S-ACP synthase. Ketoacyl-ACP synthase 
fuses the ACP-coupled C3-unit and a linear acyl-precursor together to form an initial ketoacyl-tetronate. In 
the next step, the premature tetronate moiety is acetylated by an acyltransferase, and then catalyzed by a 
dehydratase to generate an exocyclic methylene group of the mature tetronate moiety.  
 
 In addition, homologue genes of the glycerate utilization operon were found to be highly 
conserved in the biosynthetic gene cluster of spirotetronate antibiotics (Fang et al. 2008; 
Gottardi et al. 2011; Jia et al. 2006; Zhang et al. 2007) (Fig. 2.4), and closely associated with a 
particular PKS gene cluster. An in silico screening of the Micromonospora sp. NBRC 110955 
contigs using gene clusters encoding the glycerate utilization operon identified a 15.7-kb contig 
containing a set of five genes encoding a ketoacyl-ACP synthase (makB1 accession no. 
BAQ25501), a glyceryl-S-ACP synthase (makB2 accession no. BAQ25502), an acyl-carrier 
protein (ACP) (makB3 accession no. BAQ25503), an acyltransferase (makB4: accession no. 
BAQ25504), and a dehydratase (makB5 accession no. BAQ25505). (Fig. 2.4).  
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Fig. 2.4. Organization and comparison of the gene clusters for the tetronate ring formation and 
dienophile biosynthesis. mak, maklamicin; agg, agglomerin A; aby, abyssomicin; chl, chlorothricin; kij, 
kijanimicin; tca, tetrocarcin A. Genes are color-coded by the predicted function of their products: tetronate 
ring condensation (black), glycerate activation (white), and formation of an exocyclic double bond (dark gray 
and light gray). 
 
The contig also contains the makA5 gene, which encodes a type II thioesterase, homologs 
of which have been found in many other type I PKS systems and are thought to play an editing 
role in the biosynthesis of the polyketide (Heathcote et al. 2001), suggesting that these genes 
might belong to the family of maklamicin biosynthetic genes. 
To ensure full coverage of the maklamicin biosynthetic gene cluster, a cosmid library of 
1,100 clones and a BAC library of 2,700 clones were constructed and screened by PCR with 
probes of makB1 and makB5. Further cosmids were identified by chromosome walking, and the 
gaps between each contig were bridged by PCR amplification and sequencing. In total, a region 
of about 152 kb of contiguous DNA was identified in this way (Fig. 2.5). 
 
Fig. 2.5. A 152-kb DNA region from Micromonospora sp. NBRC 110955 represented by one BAC 
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clone and two cosmid clones. The arrows indicate makA1, makA4, makB1 and makB5 genes. The solid lines 
indicate the boundary of fragments from BAC2C4, cosmid 10E6, and cosmid 1E1, and the white boxes 
indicate the assembled contigs for the maklamicin biosynthetic gene cluster.  
 
Annotation analysis of the sequence and comparison with genes in public databases 
revealed 46 ORFs, the genetic organization and proposed functions of which are shown in Fig. 
2.6 and Table 2.3, respectively.  
 
Fig. 2.6. Genetic organization of the maklamicin biosynthetic gene cluster. ORFs predicted to 
participate in maklamicin biosynthesis are shaded. The proposed functions of individual ORFs are indicated 
here and summarized in Table 2.3. 
 
Six PKS genes, makA1, makA2, makA3, makA4, orf7, and orf8, were identified in the 
cluster, and are separated by the putative glycerate utilization operon (makB1-makB5). PKS 
modules encoded by the six PKS genes and the information of modules and domains of each 
PKS genes was explained on table 2.2.  
 
 
 
36 
 
Table 2.2 The PKS modules and domains from 6 PKS genes 
Genes Modules Domains 
makA1 
Loading module (L) KSQ-AT-ACP 
M1 KS-AT-DH-KR-ACP 
M2 KS-AT-DH-KR-ACP 
M3 KS-AT-DH-KR-ACP 
M4 KS-AT-DH-KR-ACP 
M5 KS-AT-DH-KR-ACP 
makA2 
M6 KS-AT-DH-KR-ACP 
M7 KS-AT-DH-KR-ACP 
M8 KS-AT-DH-KR-ACP 
M9 KS-AT-DH-ER-KR-ACP 
makA3 
M10 KS-AT-DH-ER-KR-ACP 
M11 KS-AT-DH-KR-ACP 
makA4 M12 KS-AT-ACP 
orf7 
M1 KS-AT-DH-KR-ACP 
M2 KS-AT-DH-KR-ACP 
M3 KS-AT-DH-KR-ACP 
 M4 KS-AT-DH-KR-ACP 
orf8 
M1 KS-AT-DH-KR-ACP 
M2 KS-AT-DH-KR-ACP 
 
From 19 modules of six PKS genes, only the first module of MakA1 contains a mutant 
ketosynthaseQ (KSQ) domain that should function as a malonyl-thioester decarboxylase for 
polyketide chain initiation to yield an acetyl starter unit (Bisang et al. 1999) (Fig. 2.7).  
Fig 2.7. Sequence alignment of the conserved 
motifs in KS domains from mak PKSs, Orf7, and Orf8. 
The conserved catalytic triad of C-H-H is highlighted in 
black, and the active site of KS domains is marked with 
an asterisk. The numbers indicate amino acid positions 
within each module. 
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Table 2.3. Deduced functions of ORFs in the maklamicin biosynthetic gene cluster.  
Gene Sizea Homologb and origin 
Identity/ 
similarity 
(%) 
Proposed function 
orf1 222 
TcmI (EWM63272), Micromonospora sp. 
M42 
78/86 
Polyketide synthesis 
cyclase 
orf2 407 
Micau_3627 (YP_003836729), 
Micromonospora aurantiaca ATCC 27029 
87/91 Cytochrome P450 
orf3 106 
MCBG_00403 (EWM63270), 
Micromonospora sp. M42 
89/95 
Antibiotic biosynthesis 
monooxygenase 
orf4 759 
Micau_3629 (YP_003836731), 
Micromonospora aurantiaca ATCC 27029 
79/83 Monooxygenase 
orf5 329 
AMIS_50700 (YP_005464806), 
Actinoplanes missouriensis 431 
79/86 
dTDP-glucose 4,6-
dehydratase 
orf6 291 
Micau_4024 (YP_003837123), 
Micromonospora aurantiaca ATCC 27029 
72/83 
Glucose-1-phosphate 
thymidylyltransferase 
orf7 7211 FscC (YP_007749164), S. albus J1074 46/58 Type I polyketide synthase 
orf8 3957 
ChlA5 (AAZ77698), S. antibioticus DSM 
40725 
53/62 Type I polyketide synthase 
makA4 1112 
ChlA6 (AAZ77699), S. antibioticus DSM 
40725 
60/70 Type I polyketide synthase 
makC1 502 
ChlE3 (AAZ77700), S. antibioticus DSM 
40725 
54/64 
FAD-dependent 
oxidoreductase 
makR1 516 
SCAT_p0196 (YP_004919488), S. 
cattleya NRRL 8057  
53/62 
Two-component system 
sensor kinase 
makR2 242 
SCAT_p0197 (YP_004919488), S. 
cattleya NRRL 8057  
65/73 
Two-component system 
response regulator 
makT1 275 
PyrJ4 (AFV71341), S. rugosporus NRRL 
21084 
44/60 ABC transporter permease 
makT2 306 
AMED_3162 (YP_003765355), 
Amycolatopsis mediterranei U32 
67/75 
Multidrug ABC transporter 
ATP-binding protein  
15 461 
Orf7 (CAC48373), Amycolatopsis 
balhimycina DSM 5908 
64/78 Sodium:proton exchanger  
16 345 
ChlB3 (AAZ77676), S. antibioticus DSM 
40725 
62/75 
3-Oxoacyl-ACP (acyl-
carrier protein) synthase  
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Table 2.3. Continue 
Gene Sizea Homologb and origin 
Identity/ 
similarity 
(%) 
Proposed function 
makT3 495 
ChlG (AAZ77686), S. antibioticus DSM 
40725 
51/68 
Multidrug MFS (major 
facilitator superfamily) 
transporter  
18 251 
Ndas_2938 (YP_003680854), 
Nocardiopsis dassonvillei subsp. 
dassonvillei DSM 43111 
50/61 Hypothetical protein 
19 435 
Ndas_2937 (YP_003680853), 
Nocardiopsis dassonvillei subsp. 
dassonvillei DSM 43111 
54/66 Hypothetical protein 
20 362 
Ndas_2936 (YP_003680852), 
Nocardiopsis dassonvillei subsp. 
dassonvillei DSM 43111 
68/78 ATPase AAA  
21 78 
Ndas_3539 (YP_003681446), 
Nocardiopsis dassonvillei subsp. 
dassonvillei DSM 43111 
61/72 Hypothetical protein 
22 402 
ChlC6 (AAZ77691), S. antibioticus DSM 
40725 
49/62 Glycosyltransferase 
23 185 
ChlL (AAZ77701 ), S. antibioticus DSM 
40725 
43/61 Hypothetical protein 
makA5 268 
STSU_32540 (EIF88101), S. tsukubaensis 
NRRL18488 
49/59 Type II thioesterase 
makC2 396 
ChlE2 (AAZ77695), S. antibioticus DSM 
40725 
57/66 Cytochrome P450 
makR3 276 
ChlF2 (AAZ77687), S. antibioticus DSM 
40725 
56/69 
SARP family 
transcriptional regulator  
makB1 342 
ChlM (AAZ77702), S. antibioticus DSM 
40725 
67/78 Ketoacyl-ACP synthase 
makB2 627 
ChlD1 (AAZ77703), S. antibioticus DSM 
40725 
65/75 Glyceryl-S-ACP synthase 
makB3 75 
ChlD2 (AAZ77704), S. antibioticus DSM 
40725 
61/74 ACP 
makB4 274 
ChlD3 (AAZ77705), S. antibioticus DSM 
40725 
67/75 Acyltransferase 
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Table 2.3. Continue 
Gene Sizea Homologb and origin 
Identity/ 
similarity 
(%) 
Proposed function 
makB5 362 
ChlD4 (AAZ77706), S. antibioticus DSM 
40725 
57/70 Dehydratase 
32 346 
ChlB3 (AAZ77676), S. antibioticus DSM 
40725 
66/78 3-Oxoacyl-ACP synthase  
33 1801 
ChlB1 (AAZ77673), S. antibioticus DSM 
40725 
55/85 Type I polyketide synthase 
34 86 
ChlB2 (AAZ77675), S. antibioticus DSM 
40725 
44/68 ACP 
35 446 
ChlB4 (AAZ77674), S. antibioticus DSM 
40725 
77/86 
FADH2-dependent 
halogenase  
makC3 393 
AORI_6618 (YP_008015604), 
Amycolatopsis orientalis HCCB10007 
52/66 Cytochrome P450 
makA1 9946 FscC (YP_007749164), S. albus J1074 50/61 Type I polyketide synthase 
makA2 7431 FscC (YP_007749164), S. albus J1074 47/60 Type I polyketide synthase 
makA3 3907 
ChlA5 (AAZ77698), S. antibioticus DSM 
40725 
55/65 Type I polyketide synthase 
makR4 210 
AMIS_41060 (YP_005463842), 
Actinoplanes missouriensis 431 
52/63 
TetR family transcriptional 
regulator  
41 99 
Bra471DRAFT_05239 (EHR04437), 
Bradyrhizobium sp. WSM471 
43/65 Hypothetical protein 
makA6 239 
SAV_1748 (NP_822924), S. avermitilis 
MA-4680 
59/68 
4'-Phosphopantetheinyl 
transferase 
makA7 283 
SCAB_84081 (YP_003493881), S. scabiei 
87.22 
72/80 Metallophosphoesterase  
makD1 463 
Micau_2481 (YP_003835596), 
Micromonospora aurantiaca ATCC 27029 
66/73 Acyl-CoA synthetase 
45 94 
ML5_5878 (YP_004085486), 
Micromonospora sp. L5 
61/79 Hypothetical protein 
makD2 474 
Strop_2764 (YP_001159584), Salinispora 
tropica CNB-440 
68/78 
Propionyl-CoA 
carboxylase 
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To confirm the involvement of makA1 in the maklamicin biosynthesis, we generated a 
makA1 disruptant (ΔmakA1) in which a region encoding the first module of MakA1 was 
replaced with an oriT-aac(3)IV cassette by using λRED-mediated PCR-targeted mutagenesis 
(Fig. 2.8). The successful disruption of makA1 gene was checked by PCR using primer pair 
makA1-cFw and makA1-cRe (Fig. 2.8). The makA1 disruptant was confirmed the production 
of maklamicin by HPLC analysis. Based on HPLC result, the ΔmakA1 strain lost maklamicin 
production (Fig. 2.9), which clearly showed that makA1 is responsible for the maklamicin 
biosynthesis and suggested that makA2 and makA3, probably organized in a polycistronic 
operon with makA1, are also involved in the maklamicin biosynthesis.  
 
 
Fig. 2.8. Disruption of the mak PKS genes in the Micromonospora sp. NBRC 110955. (a) 
Schematic representation of the strategy for gene disruptions of makA1 and makA4. The oriT sequence is the 
RK2 origin of transfer, and the aac(3)IV gene confers apramycin resistance. (b) PCR analysis to confirm 
gene-disruption of the makA1 and makA4 genes. ΔmakA1, makA1 disruptant; ΔmakA4, makA4 disruptant. 
With the primer pair makA1-cFw/makA1-cRe, an internal fragment (3,430 bp) of the intact makA1 gene or 
a fragment (1,610 bp) containing the oriT-aac(3)IV cassette was amplified by PCR, respectively. With the 
primer pair makA4-cFw/makA4-cRe, an internal fragment (3,454 bp) of the intact makA4 gene or a fragment 
(2,377 bp) containing the cassette was amplified by PCR, respectively.  
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Three PKS genes, makA1, makA2, makA3, encode the modular PKSs that consist of 11 
active modules (including a loading module) with an inactive module (see below). Based on 
the structure of maklamicin, 12 PKS modules were predicted to be involved in the polyketide 
assembly process. Thus, through gene inactivation, we investigated the involvement of the 
makA4 gene encoding a single PKS module (Fig. 2.8). Like the ΔmakA1 strain, the ΔmakA4 
strain was unable to produce maklamicin (Fig. 2.9), indicating that the PKS module encoded 
by makA4 is required for the maklamicin biosynthesis, and four PKS genes (makA1-makA4) 
are responsible for the polyketide assembly of maklamicin. 
 
Fig. 2.9. Maklamicin production analyzed by the gene disruption of makA1 and makA4. HPLC 
chromatograms of the Micromonospora sp. NBRC 110955 extracts are shown. WT, wild-type strain; ΔmakA1, 
makA1 disruptant; ΔmakA4, makA4 disruptant; maklamicin, an authentic standard of maklamicin. mAU, 
milliabsorbance units at 254 nm. Peaks corresponding to maklamicin are indicated by a heavy dot.  
 
 In contrast, disruption of the remaining PKS genes, orf7 or orf8, located upstream of 
makA4, had no effect on the production of maklamicin (Fig. 2.10). These PKS genes appear to 
be involved in the production of another, as yet unidentified, polyketide compound.  
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2.3.2. Genes involved in the polyketide assembly of maklamicin  
To predict the polyketide assembly process in the biosynthetic pathway of maklamicin, 
four PKSs (MakA1-MakA4) were analyzed in silico, and were found to contain 63 enzymatic 
domains organized into 13 PKS modules (Table 2.2). 
Regards to figure 2.7, the first module of MakA1 contains a mutant KSQ domain for 
decarboxylation of the ACP-bound malonate unit to form an acetyl group at the initiation of 
polyketide chain assembly, and thus functions as a loading module. The presence of the 
conserved active site (catalytic triad of Cys-His-His) in other KS domains (Fig. 2.7) indicates 
that they all function in the condensation steps (He et al. 2000)  
Based on the sequence analysis of the acyltransferase (AT) domain within each module, 
the substrate specificities of the AT domains were predicted; the results showed that the AT 
domains of modules 2, 5, 7, 8, 10 and 12 as well as the loading module are specific for malonyl-
CoA, whereas the AT domains of the remaining extender modules are specific for 
methylmalonyl-CoA (Fig. 2.11). 
Fig. 2.10. Maklamicin production in the wild-type strain (WT), 
the orf7 disruptant (Δorf7) and the orf8 disruptant (Δorf8). HPLC 
chromatograms of Micromonospora sp. NBRC 110955 extracts are 
shown. mAU, milliabsorbance units at 254 nm. The peaks of maklamicin 
and an unidentified polyketide compound are indicated as a black arrow 
and a gray arrow, respectively.  
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Fig. 2.11. Analysis of the AT domains from the maklamicin PKSs by phylogenetic tree and amino 
acid alignment. (a) Phylogenetic tree constructed by the unweighted pair group method with arithmetic mean. 
Multiple sequence alignment was conducted with the CLUSTALW program 
(http://www.genome.jp/tools/clustalw/). The corresponding domains are as follows ChlA1/ChlA3/ChlA5 for 
chlorothricin in S. antibioticus DSM 40725. (b) Sequence alignment of the conserved motifs in AT domains. 
Three dominant motifs, composed of 6, 6, and 4 amino acid residues, are assigned in each AT domain. The 
conserved amino acid residues are highlighted in gray. The numbers indicate amino acid positions within 
each module. 
 
In contrast, an unusual AT domain was identified in module 1 of MakA1, in which an 
extra stretch of 62 amino acid residues including a polyalanine region (11 successive alanine 
residues) was found between the conserved motifs (Fig. 2.12), implying that this AT domain 
could be inactive, and an acetyl group on the loading module is directly transferred to a 
malonyl-S-ACP in module 2 by skipping module 1. These predicted substrates in the 
biosynthetic machinery for maklamicin are generally consistent with the structure of 
maklamicin. Regarding ACP domains, all the 13 ACP domains contain a signature motif around 
the conserved 4’-phosphopantetheine attachment site Ser residue (Fig. 2.13a) (Lai et al. 2006) 
 
44 
 
 
Fig. 2.12. Sequence alignment of the conserved motifs in AT domains from the mak PKSs and the 
chlorothricin PKSs. Multiple sequence alignment was conducted with the CLUSTALW program. Asterisks, 
identical or conserved residues in all sequences in the alignment; colons, conserved substitutions; single dots, 
semi-conserved substitutions. Three dominant motifs, composed of 6, 6, and 4 amino acid residues, are 
highlighted in gray. The extra stretch of 62 amino acid residues in the AT domain (module 1 of MakA1) is 
shown in a box with a polyalanine region (11 successive alanine residues) with black highlighting. 
 
In addition, makA6 and makA7, which are located downstream of the maklamicin PKS 
genes makA1-makA3, encode 4’-phosphopantetheinyl transferase and phosphoesterase, 
respectively. These two genes may be required for turnover of the 4’-phosphopantetheinyl 
group during the activation process of ACP domains (Murugan et al. 2010). Of the 11 predicted 
dehydratase (DH) domains found in the PKS modules, 2 DH domains (DH1 and DH2) contain 
a mutation in the conserved motif in which the active site His is replaced by other residues (Fig. 
2.13b) (Wu et al. 2005), indicating that these DH domains should be inactive and the module 2 
of MakA1 generates a hydroxy group by function of the ketoreductase (KR) domain (KR2). 
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Sequence analysis revealed that KR2 contains the stereochemistry signature “L(V)DD” motif 
for B-type KR domains to produce a hydroxy group of R configuration (Fig. 2.13c) (Caffrey 
2003), which correlates with the stereochemistry of the C-31 hydroxy group in maklamicin. 
The two enoylreductase (ER) domains, ER9 in module 9 of MakA2 and ER10 in module 10 of 
MakA3, contain the conserved NADP(H)-binding site (Fig. 2.13d) (Cane 2010), and are likely 
responsible for the reduction of a double bond between C-8/C-9 and C-6/C-7, respectively.  
 
 
 
 
Fig. 2.13. Amino acid alignment of ACP, DH, KR and ER domains. The numbers indicate amino 
acid positions within each module. (a): Sequence alignment of the conserved motif in ACP domains. The Ser 
residues as the phosphopantheteine binding site are highlighted in gray. (b) Sequence alignment of the 
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conserved motif in DH domains. An asterisk indicates the proposed active-site His in the DH domain, and 
the DH domains of module 1 and module 2 lack the active site His residue. (c) Sequence alignment of the 
conserved motifs in various B-type KR domains. The names are: PimS2, pimaricin; NysI, nystatin; EpoC, 
epothilone; RapsB, rapamycin; RifD, rifamycin. The conserved N-terminal NADP(H) binding motif is 
underlined (GxGxxGxxxA). The stereochemistry signature “LDD” motifs for B-type KR domains are 
highlighted in gray. The PN motifs are shown in bold type. (d) Sequence alignment of the conserved motif 
in ER domains. The proposed NADP(H)-binding site (LxHxxxGGVG) is highlighted in gray. The names and 
sequence accession numbers are shown in Appendix. 
 
Consequently, for the biosynthesis of maklamicin, four PKSs (MakA1-MakA4) could 
catalyze the formation of the nascent linear polyketide intermediate through the successive 
decarboxylative condensations (Fig. 2.14). We postulated that the linear maklamicin 
intermediate undergoes an intramolecular Diels-Alder reaction by addition of the C-4/C-5 
dienophile to the C-10/C-13 diene to yield the trans-decalin moiety. Further, we considered that 
an acyl-CoA synthetase (MakD1) and a propionyl-CoA carboxylase (MakD2) were responsible 
for the supply of precursors such as malonyl-CoA and methylmalonyl-CoA in the polyketide 
chain assembly, respectively.  
 
Fig. 2.14. Polyketide chain extension on the maklamicin PKSs encoded by makA1, makA2, makA3 
and makA4. The circles represent enzymatic domains in the PKS polypeptide; KS, ketosynthase; KSQ, KS in 
which the active site Cys is replaced by Gln; AT, acyltransferase; DH, dehydratase; ER, enoylreductase; KR, 
ketoreductase; ACP, acyl carrier protein. The presumed inactive AT and DH domains of module 1 and module 
2 are shaded in black.  
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2.3.3. Biosynthesis of the tetronate moiety of maklamicin  
Five genes (makB1-makB5) are subclustered in the middle of the maklamicin biosynthetic 
gene cluster. Comparison with the glycerate utilization operon for the biosynthesis of other 
tetronate compounds suggested that these five genes are involved in biosynthesis of the 
tetronate moiety in maklamicin. In particular, both the sequence and organization of the makB 
genes were well coincident with those of agg genes (Fig. 2.4), the functions of which were 
recently characterized biochemically in the biosynthesis of agglomerin A (Kanchanabanca et al. 
2013). MakB2, a putative glyceryl-S-ACP synthase showing both glyceryltransferase and 
phosphatase activities, activates 1,3-bisphosphoglycerate from the glycolytic pathway by 
loading onto the discrete ACP MakB3, yielding a glyceryl-S-ACP (Fig. 2.15). The putative 
ketoacyl-ACP synthase MakB1 catalyzes the condensation between the glyceryl-S-ACP and the 
polyketide intermediate to form the next maklamicin intermediate, which has the premature 
tetronate moiety with a trans-decalin moiety. Subsequently, the premature tetronate moiety 
could be acetylated by the putative acyltransferase MakB4, and then catalyzed by the putative 
dehydratase MakB5 to generate the exocyclic double bond of the mature tetronate moiety.  
 
Fig. 2.15. Proposed pathway for maklamicin biosynthesis in the Micromonospora sp. NBRC 
110955. 
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2.2.4. The tailoring steps of maklamicin biosynthesis  
Prior to the generation of the cyclohexene moiety, the C-14/C-17 conjugated diene 
structure in the maklamicin intermediate would be reduced and converted to a single double 
bond between C-15 and C-16. Although the conversion of the diene structure seems to be 
indispensable for the maturation step in the maklamicin biosynthesis (see Discussion), the exact 
order of this double-bond transfer process remains to be unraveled. I postulated that the reduced 
intermediate is cyclized by the second Diels-Alder reaction between the exocyclic double bond 
of the tetronate moiety as a dienophile and a conjugated C-18/C-21 diene structure in the tail 
region to yield a premature maklamicin macrocycle showing a cyclohexene moiety. The gene 
products of both makC2 and makC3 strongly resembled cytochrome P450 monooxygenases, 
suggesting that either makC2 or makC3 or both might be associated with the post-modifications 
of maklamicin biosynthesis. Based on an experiment described in Chapter 3 indicated that 
MakC2 is required for the specific hydroxylation at C-29, which is probably the final step in 
the biosynthetic pathway of maklamicin.  
 
2.2.5. Genes putatively involved in the regulation and the self-resistance of maklamicin 
biosynthesis  
The in silico analysis of the mak gene cluster identified four genes coding for potential 
pathway-specific regulators in the control of the maklamicin biosynthesis. The proteins 
encoded by makR1 and makR2 are homologous to various sets of sensor kinases and cognate 
response regulators belonging to a bacterial two-component signal transduction system for 
detecting and responding to changes in the environment (Mascher et al. 2006). The deduced 
protein of makR3 resembled transcriptional activators of the Streptomyces antibiotic regulatory 
protein (SARP) family that have been shown to positively control the production of antibiotics 
as cluster-situated regulators (Wietzorrek and Bibb 1997). This finding suggested the possibility 
that MakR3 positively regulates the production of maklamicin. A fourth regulatory gene, 
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makR4, was presumed to encode a transcriptional regulator of the TetR family (Ramos et al. 
2005). Homologues of the makR4 gene were found to be located inside the biosynthetic gene 
clusters of spirotetronate antibiotics possessing the trans-decalin moiety (chlF1 for 
chlorothricin; tcaR2 for tetrocarcin A; kijA8 and kijC5 for kijanimicin). Although the role of 
these putative regulators remains to be investigated, the high conservation of TetR-family 
regulatory genes implied that they might be common regulators for the production of those 
spirotetronate antibiotics, including maklamicin. MakT1 and MakT2 are homologous to 
members of ATP-binding-cassette (ABC) transport systems (Davidson and Chen 2004), and 
MakT3 is homologous to members of the multidrug MFS (major facilitator superfamily) 
transporters (Putman et al. 2000). Interestingly, in addition to regulators of the TetR family, the 
MFS transporter genes have also been identified in the biosynthetic gene clusters of 
chlorothricin, tetrocarcin A, and kijanimicin, suggesting that MakT3 might serve as the efflux 
pump for maklamicin as a self-resistance mechanism.  
 
2.4. Discussion  
The spirotetronate-class antibiotics have distinct chemical structures that include a 
tetronate moiety spiro-linked to a cyclohexene ring, sometimes conjugated with a trans-decalin 
moiety (Vieweg et al. 2014). In particular, the spirotetronates containing the trans-decalin 
moiety are characterized by a carbon chain length connecting the cyclohexene and the decalin 
units, which, together with the addition of several deoxy sugars and/or modification of other 
peripheral moieties, lead to the diversity of structures and biological activities, such as anti-
microbial and anti-tumor activities. All representatives of the spirotetronates share these 
important structural characteristics, which supports the assumption that their main frameworks 
are biosynthesized by employing common polyketide assembly lines and glycerate utilization 
systems. In the present study, we successfully identified the biosynthetic gene cluster of 
maklamicin, one of the spirotetronates including the trans-decalin moiety, and proposed a 
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biosynthetic model composed of a polyketide assembly line, a glycerate utilization system and 
tailoring modifications. Furthermore, the identification of maklamicin biosynthetic genes 
enabled us to genetically compare the spirotetronate gene clusters to deduce common or unique 
biosynthetic pathways of spirotetronates.  
Maklamicin has two structural features that are unique among the spirotetronates: a 2R-
hydroxy-propyl group at C-21 and the shortest carbon chain length between the two ring 
systems. The 2R-hydroxy-propyl group of maklamicin is attached on the cyclohexene ring, 
whereas other spirotetronates have an achiral substituent at the same position, such as a methyl, 
a formyl, an ethyl, or an n-propyl group (Hegde et al. 1997; Momose et al. 1999; Park et al. 
2007; Shimotohno et al. 1993). The attachment of a hydroxy group to the alkyl chain to form a 
peripheral moiety of a polyketide compound has been known to be catalyzed by specific 
enzymes in the post-PKS tailoring step (Rix et al. 2002). For example, the hydroxylation at C-
29 in maklamicin, which appears to be the final step of the biosynthetic pathway, requires 
MakC2, a putative cytochrome P450 monooxygenase (see Chapter 3). However, the detailed 
analysis of maklamicin PKS modules demonstrated that the C-31 hydroxy group is formed on 
the nascent linear polyketide intermediate, by the cooperative function of both an inactive DH2 
domain and a B-type KR2 domain. In the polyketide assembly lines of other representative 
spirotetronates (chlorothricin, kijanimicin, and tetrocarcin A), these initial processes have 
active DH domains that catalyze the generation of an enoyl group in the tail-region of the 
polyketide backbone (Fang et al. 2008; Jia et al. 2006; Zhang et al. 2007). Thus, the irregular 
PKS modules provide maklamicin with a unique stereogenic center on the substituent of the 
cyclohexene ring.  
Maklamicin, which is classified as a small-sized spirotetronate, consists of a central ring 
system containing an 11-membered carbon macrocycle. With respect to the carbon chain 
between the cyclohexene and the decalin units, a four-carbon chain linker of maklamicin, in 
addition to the similar four-carbon chain linkers in nomimicin (Igarashi et al. 2012) and 
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PA46101 compounds (Matsumoto et al. 1989) , are the shortest ever such carbon chains 
reported in the family of spirotetronates. The ring size in the central ring system is dependent 
on the relative positional relationship between a conjugated pair of double bonds in the tail-
region of the polyketide backbone and an exocyclic double bond at the C5-position of the 
tetronate moiety for undergoing Diels-Alder cycloaddition (Vieweg et al. 2014). The 
biosynthetic pathways of chlorothricin, kijanimicin, and tetrocarcin A have illustrated that the 
terminal diene structure is biosynthesized in the early steps of the pathway by two PKS modules 
(module 1 and module 2) containing two active DH domains. The DH domain in maklamicin 
PKS module 2, one of the corresponding modules, is rendered inactive by the replacement of 
the active site (Fig. 2.13b), which leads to macrocyclization by the second Diels-Alder reaction 
between the C-18/C-21 diene structure formed by modules 3 and 4 and the dienophile of the 
tetronate moiety to generate a cyclohexene ring. The maklamicin PKS assembly line shows the 
same number of PKS modules as observed in chlorothricin, kijanimicin, and tetrocarcin A, and 
their trans-decalin moieties are generated by the same polyketide assembling system via the 
first Diels-Alder reaction. Nonetheless, because the second Diels-Alder reaction in the 
maklamicin biosynthesis occurs with the alternative diene formed by different PKS modules, 
the carbon-chain linker in maklamicin is the shortest in the spirotetronates.  
Another structural difference that distinguishes maklamicin from other spirotetronates is 
the presence of the C-15/C-16 double bond, which appears to be synthesized via some pathway 
other than the canonical PKS system. The corresponding double bond is also found in the 
structure of nomimicin, suggesting that a common mechanism underlies the biosynthesis of 
maklamicin and nomimicin. The conversion from a C-14/C-17 diene to the C-15/C-16 double 
bond would be a significant event for the macrocyclization between the C-18/C-21 diene and 
the exocyclic double bond of the tetronate moiety, because the diene structure presumably 
prefers to be located at a position proximal to the dienophile double bond. A PKS module 
encompassing the pair of a B-type KR domain and a DH domain typically generates polyketide 
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chain elongation intermediates with a trans (E) double bond (Li et al. 2009; Wu et al. 2005). 
Our finding that all maklamicin KR domains belonged to the B group (Fig. 2.13c) indicated 
that the maklamicin polyketide intermediate has trans double bonds that situate the C-18/C-21 
diene distal to the dienophile (Fig. 2.15), when the C-14/C-17 diene is intact. The conversion 
of the C-14/C-17 diene to the C-15/C-16 double bond could provide the positional flexibility 
of the C-18/C-21 diene for easy access to the dienophile for performing the Diels-Alder reaction, 
but it remains to be determined which enzymes are responsible for the double bond transfer. A 
detailed genetic comparison among the gene clusters of maklamicin with nomimicin and 
spirotetronates lacking the C-15/C-16 double bond will elucidate the molecular mechanisms 
for the biosynthesis of the C-15/C-16 double bond.  
The insights afforded by our identification and characterization of the maklamicin 
biosynthetic genes should open the way to a future comparative analysis with the biosynthetic 
genes of spirotetronates with or without the trans-decalin moiety to account for the structural 
commonalities and differences, and the production systems. Genes encoding a transcriptional 
regulator of the TetR family and an MFS transporter are well-conserved among the gene clusters 
of maklamicin, chlorothricin, kijanimicin, and tetrocarcin A, suggesting that these two genes, 
in addition to the biosynthetic genes for the polyketide backbone and the tetronate moiety, play 
a common role in the production of the spirotetronates. The recent studies reported intriguing 
enzymes for performing a Diels-Alder reaction, which demonstrated that VstJ catalyzes the 
stereoselective [4+2]-cycloaddition for the formation of spirotetronate structure in the 
versipelostatin biosynthesis (Hashimoto et al. 2015), and that ChlE3 is a dialkyldecalin synthase 
and ChlL is a spiro-conjugate synthase in the chlorothricin biosynthesis (Tian et al. 2015). These 
findings strongly suggests that Orf23, a homologue of VstJ and ChlL, catalyzes the formation 
of cyclohexene unit in the maklamicin biosynthesis and that MakC1, a ChlE3 homologue, 
catalyzes the formation of trans-decalin moiety. The genetic information of these conserved 
genes could be useful in genome mining and screening for the rapid identification of 
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actinobacteria producing new spirotetronates. Further understanding of the maklamicin 
biosynthetic machinery will enable us to apply combinatorial biosynthesis for the rational 
development of novel maklamicins and will facilitate expansion of the structural repertoire in 
the family of spirotetronate antibiotics.  
 
2.5. Summary 
In this chapter, maklamicin biosynthetic gene cluster were identified from 
Micromonospora sp. NBRC 110955. The gene cluster spans around 152 kb consists of 46 ORFs. 
The disruption of polyketide synthases genes, makA1and makA4 resulted the complete loss of 
maklamicin production suggested the gene cluster is involved in maklamicin biosynthesis. 
Consequently, 24 genes can be assigned to have roles in the maklamicin biosynthesis including 
polyketide framework (makA1-makA7 and makD1-makD2), spirotetronate (makB1-makB5) and 
peripheral moieties (orf23, makC1-makC2), self-resistance (makT1-makT3) and regulation 
(makR1-makR4) of maklamicin production. The proposed maklamicin biosynthesis indicated 
the inactivation of DH domain at initial module affecting the structure differentiation of 
maklamicin.       
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Chapter 3 
 
29-Deoxymaklamicin, a new maklamicin analogue produced by a 
genetically engineered strain Micromonospora sp. NBRC 110955 
 
3.1. Introduction 
Polyketide natural products constitute an important group of secondary metabolites used 
in human/veterinary medicine and agriculture (Staunton and Weissman 2001). These products 
are typically biosynthesized in a step-by-step manner by several kinds of enzymes: polyketide 
synthases (PKSs) and tailoring enzymes for post-PKS modifications such as glycosylation, 
methylation, and hydroxylation (Olano et al. 2010). Among the tailoring enzymes, the 
cytochrome P450 monooxygenases are known to be involved in the regiospecific and 
stereospecific oxidation of polyketide compounds (Lamb et al. 2013). This enzymatic reaction 
is an important biosynthetic process of the polyketide compounds which renders them 
structurally diverse and provides them with desirable bioactivities.  
Maklamicin is one of the spirotetronate-class antibiotics, a growing family of polyketide 
compounds with a wide range of biological activities, and shows anti-microbial activity against 
Gram-positive bacteria (Igarashi et al. 2011). Maklamicin consists of a polyketide scaffold with 
a tetronate moiety spiro-linked to a cyclohexene ring conjugated with a trans-decalin moiety. 
From chapter 2, I have recently identified the maklamicin biosynthetic (mak) gene cluster from 
the Micromonospora sp. NBRC 110955. This gene cluster includes four type I PKS genes 
(makA1-makA4) for the polyketide assembly and the glycerate utilization operon (makB1-
makB5) for incorporation of the tetronate moiety, as well as putative genes involved in the 
regulation and self-resistance of this species. Furthermore, the homologues of VstJ which 
catalyses the stereoselective [4+2]-cycloaddition in the versipelostatin biosynthesis (Hashimoto 
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et al. 2015) and ChlE3 which is a diakyldecalin synthase and ChlL is a spirotetronate synthase 
in the chlorothricin biosynthesis (Tian et al. 2015) are present inside the mak gene cluster as an 
Orf23 (homologue of VstJ and ChlL) and MakC1 (homologue of ChlE3), suggesting that Orf23 
and MakC1 are probably responsible for the formation of the spirotetronate structure. In 
addition to these genes, the mak cluster contains two more genes (makC2 and makC3) encoding 
the cytochromes P450, which may participate in post-PKS modification in the maklamicin 
biosynthesis.  
 
 
Fig 3.1. Structure of 29-deoxymaklamicin  
 
3.2. Materials and methods 
3.2.1. Bacterial strains, plasmids, and growth conditions 
Micromonospora sp. NBRC 110955 (Igarashi et al. 2011) was grown at 30oC on ISP 
medium 2 (Becton, Dickinson and Company, Franklin Lakes, NJ, USA). Escherichia coli DH5α 
was used for general DNA manipulation (Sambrook and Russell 2001), the DNA methylation-
deficient E. coli strain ET12567 containing the RP4 derivative pUZ8002 (Paget et al. 1999) 
was used for E. coli/Micromonospora conjugation, and E. coli F- dcm Δ(srl-recA)306::Tn10 
carrying pUB307-aph::Tn7 was used for E. coli/Streptomyces conjugation. E. coli strains were 
grown in 2X yeast extract-tryptone medium, with appropriate antibiotics when necessary. 
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pIJ773 (Gust et al. 2003) was used to PCR amplify the oriT-aac(3)IV cassette for gene 
disruption, and pLT101, which contains the constitutive and strong promoter ermEp* and a tfd 
terminator (Pulsawat et al. 2007), was used to construct a vector for genetic complementation. 
Micromonospora sp. NBRC 110955 was cultivated in a test tube (15 by 160 mm) containing 5 
mL of liquid ISP2 medium (0.2% yeast extract, 1% malt extract and 0.2% glucose, pH 7.2). 
The test tube was incubated on a reciprocal shaker (160 spm) at 30oC for 5 days. An aliquot 
(700 μL) of the culture was then inoculated into 70 mL of liquid ISP2 medium in a 500 mL-
baffled flask on a rotary shaker (170 rpm), and mycelia were harvested after 36 h of cultivation 
at 30oC. The mycelia were washed, resuspended in fresh liquid ISP2 medium, and stored at -
80oC until use as a seed culture. All the primers are listed in table 3.1. 
 
3.2.2. Genetic disruption in the Micromonospora sp. NBRC 110955 
The makC2 and makC3 disruptants were constructed by a RED-mediated PCR-targeted 
gene disruption protocol (Fig. 2.2, chapter 2) (Gust et al. 2003) using the following primer pairs: 
makC2-Fw and makC2-Re for makC2 disruption; and makC3-Fw and makC3-Re for makC3 
disruption. The amplified DNA containing the oriT-aac(3)IV disruption cassette of pIJ773 was 
introduced into the cosmid 10E6 for makC2 or the cosmid 1E1 (Fig 2.5, chapter 2) for makC3 
using λRED-mediated recombination with E. coli BW25113/pIJ790 (Gust et al. 2003). The 
disrupted cosmids were transferred via E.coli ET12567/pUZ8002 to the Micromonospora sp. 
NBRC 110955 by intergeneric conjugation. The genotype of candidates for disruption of the 
corresponding genes was confirmed by PCR analysis. The Micromonospora sp. NBRC 110955 
makC2 and makC3 disruptants were abbreviated ΔmakC2 and ΔmakC3, respectively.  
 
3.2.3. Genetic complementation of the makC2 disruptant 
The apramycin resistance gene aac(3)IV of pLT101 was replaced by the hygromycin 
resistance gene hyg using the λRED-mediated recombination, yielding pLT129 as a vector for 
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complementation of the ΔmakC2 strain. The makC2 gene was PCR-amplified by the primer 
pair makC2-comp-Fw/makC2-comp-Re and then cloned into the BamHI site of pLT129 using 
a GeneArt Seamless Cloning and Assembly Kit (Life Technologies, CA, USA), resulting in 
pLT130. The plasmid pLT130 was introduced into the ΔmakC2 strain by intergeneric 
conjugation and integration. Integration of the plasmid was confirmed by hygromycin 
resistance gene (primers were showed in table 3.1) and PCR analysis.  
 
3.2.4. Analysis of maklamicin production  
The seed culture of Micromonospora sp. NBRC 110955 was cultivated in a 500 mL-
baffled flask containing 100 mL of V-22 medium (Igarashi et al. 2011). The baffled flask was 
incubated on a rotary shaker at 30oC for 4 days. An aliquot (3 mL) of the culture was then 
inoculated into 100 mL of A11M medium (Igarashi et al. 2011) in a 500 mL-baffled flask. After 
6 days of cultivation, the culture broth was extracted with a half volume of 1-butanol. After the 
organic layer was evaporated and the residue dissolved with methanol, the crude extract was 
subjected to reversed-phase HPLC on a CAPCELL-PAK C18 column (UG80; 5 μm; 4.6 by 250 
mm; Shiseido, Tokyo, Japan) developed with a gradient system of CH3CN (75% for 0-5 min; 
75% to 95% for 5-25 min) containing 0.1% HCO2H (flow rate, 1.2 ml/min; UV detection, 254 
nm). Purified maklamicin was used as a standard for HPLC analysis.  
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Table 3.1. Oligonucleotides used in this study 
Primer Sequence (5`-3`) 
For construction of makC2 disruptant 
makC2-Fw 
GACTAGTCGGTCCACCGCGCCTGACCGCCCGTTCCGGCCAAGGGCTAATTCCGGG
GATCCGTCGACC 
makC2-Re 
CGTCTAGACGTCGCGCGCTTCCGCTACCCCCTCGTAAGGAGGCTTCATGTGTAGG
CTGGAGCTGCTTC 
makC2-cFw GGGTGAGGTGCTGGCCCAGGCACTGGT 
makC2-cFw TTCGACCCCCCGGAGGAGTTGGCATCGC 
makC2-tFw ACGACCTGCTGGTCTGCCACAGCTACA 
makC2-tRe TCTACCAGAACGCACGCGCCGTGCTCAGT 
For construction of makC3 disruptant 
makC3-Fw 
GACTAGTCGAGATCCGGGCCGGGCTTCGGCGGTTGCGGGGTCGGTCAATTCCGGG
GATCCGTCGACC 
makC3-Re 
CGTCTAGACGTGCCTCCCCTTTAGTCGGCGCGCCGACGATGGCGGGATGTGTAGG
CTGGAGCTGCTTC 
makC3-cFw GCAGCGACTCCCAGCCGTTCATCAGGAT 
makC3-cFw ATGAGCAGCGACGTCCTGCACAGCAAC 
makC3-tFw ACGTACTGAAGATGCTCCAGGGCGACGT 
makC3-tRe CTCACTCGGCCTCGTACGGACGCCGT 
For genetic complementation of the makC2 disruptant 
makC2-comp-Fw CGTGCCGGTTGGTAGGAGGCTTCATGACCGACCTC 
makC2-comp-Re CTTTAGATTCTAGAGCTACCAGCGCACCGGCAGGC 
hyg-Fw CTACGCGGAGCCTGCGGAACGAC 
hyg-Re GAGCAGCGCGGCCAGGATCTCGC 
For transcriptional analysis of makC2 in the recombinant S. avermitilis 
hrdB-Fw ACTCGCTGTCACCGTCCTCAC 
hrdB-Re CGCGCCAAGAACCACCTCCT 
59 
 
3.2.5. Isolation and structure elucidation of a new maklamicin analogue 
The seed culture of was ΔmakC2 strain was cultivated in a 500 ml baffled flask containing 
100 ml of V-22 medium (Igarashi et al. 2011). The baffled flask was incubated on a rotary 
shaker at 30oC for 4 days. An aliquot (3 ml) of the culture was then inoculated into 100 ml of 
A11M medium, (Igarashi et al. 2011) in a 500 ml baffled flask, in total 2 liters of culture. After 
6 days of cultivation, 2 liters of culture broth was extracted with a half volume of 1-butanol, 
after which the 1-butanol layer was evaporated to dryness. The crude extract (1.56 g) was 
subjected to silica gel column chromatography with a step gradient of CHCl3/MeOH (1:0, 20:1, 
10:1, 4:1, 2:1, 1:1 and 0:1 v/v). Fractions 3 and 4 were combined and concentrated to give 358 
mg of brown oil. Final purification was achieved by preparative C-18 HPLC using an XTerra 
RP18 column (5 μm; 10 by 150 mm; Waters, MA, USA) with 70% CH3CN/0.1% HCO2H at 3 
mL/min and detection at 210 nm, to yield 5.3 mg of purified compound with a retention time 
of 38.5 min.  
 
3.2.6. Chemical and analytical methods 
The UV spectrum was recorded on a Hitachi U-3000 spectrophotometer. The IR spectrum 
was recorded on a FTIR-8400 S (Shimadzu, Kyoto, Japan). Optical rotation was measured on 
a JASCO P-1020 polarimeter. HRFABMS was measured on a JEOL JMS-700 spectrometer. 
NMR (1H, 600 MHz; 13C, 150 MHz) spectra were recorded on a Bruker UltraShield 600 Plus 
spectrometer and the 1H and 13C chemical shifts were referenced to the solvent signal (δH 7.26 
and δC 77.0 in CHCl3).  
 
3.2.7. Biological assays 
29-Deoxymaklamicin was tested in antimicrobial assays against Bacillus cereus 
NBRC15305, Bacillus subtilis PCI219, Candida albicans NBRC1594, Enterococcus faecalis 
NBRC100480, Escherichia coli NIH-JC2, Micrococcus luteus ATCC9343, and Staphylococcus 
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aureus NBRC12732. Mueller Hinton broth (Difco, Detroit, MI, USA) was used for bacteria, 
and Yeast Nitrogen Base (Difco) supplemented with 2% glucose was used for C. albicans. Test 
microorganisms were inoculated into a 32-mL test tube containing 8 mL of the liquid medium. 
After incubation on a reciprocal shaker for 20 h at 30oC, the cells were collected by 
centrifugation and the cell suspension (1.0 x 105 cells/mL) was prepared in saline. The liquid 
medium (135 μL), the cell suspension (15 μL), and the sample solution in DMSO (0.5 to 1 μL) 
were added into the wells of a 96-well culture plate and were mixed by gentle agitation. After 
incubation for 20 h at 37oC (for E. coli) or 30oC (for other bacteria and C. albicans), the 
absorbance at 650 nm was measured using a microplate reader. The concentrations of 29-
deoxymaklamicin used for testing biological assay were 0.195, 0.391, 0.781, 1.56, 3.13, 6.25, 
12.5, 25, 50 and 100 g/ml respectively.    
 
3.2.8. Resting cell conversion with S. avermitilis expressing makC2  
The plasmid pLT130 was introduced into S. avermitilis SUKA22 (Komatsu et al. 2013) 
by intergeneric conjugation, followed by hygromycin selection and PCR analysis. Spores (1.0 
x 108 CFU) of S. avermitilis strains were cultivated in a test tube (15 by 160 mm) containing 2 
mL of APM medium (Kitani et al. 2009) at 28oC for 2 days. An aliquot (700 μL) of the culture 
was inoculated into 70 mL of APM medium in a 500 mL-baffled flask, and mycelia were 
harvested after 2 days of cultivation. The 10 ml of cell culture was centrifuged and the 
mycelium was collected and washed twice with 50 mM potassium phosphate buffer (pH 7.2), 
and then the mycelia (1 gram wet-cell weight) was resuspended in 10 mL of 100 mM potassium 
phosphate buffer (pH 7.2) (Choi et al. 2012) supplemented with 0.5 mg of 29-deoxymaklamicin. 
The sample was incubated on a reciprocal shaker (185 spm) at 28oC for 3 days, and extracted 
with a half volume of 1-butanol. The 1-butanol layer was concentrated to dryness under a 
vacuum, and the residue was dissolved in methanol and subjected to HPLC analysis by the 
same procedure as for the detection of maklamicin.  
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For gene expression analysis, 10 ml from 70 ml culture remained from resting cell 
conversion assay was used for RNAs extraction by an RNeasy Mini kit (QIAGEN Science, MD, 
USA) and treated with DNase I (Takara Bio, Shiga, Japan). The cDNA was synthesized using 
SuperScript III RNase H- reverse transcriptase (Invitrogen, CA, USA) and random primers 
(Invitrogen) according to the manufacturer’s instructions. The PCR amplification was 
performed by using GoTaq Green Master Mix (Promega KK, Tokyo, Japan) under the following 
conditions: 98oC for 2 min, followed by 25 cycles of 98oC for 30 s, 57oC for 30 s, and 72oC for 
1 min. The primers used for the detection of the makC2 transcript were makC2-cFw and 
makC2-cRe. The absence of DNA contamination was confirmed by RT-PCR without reverse 
transcriptase.  
 
3.3. Results 
3.3.1. Features of two putative cytochrome P450 genes, makC2 and makC3 
A homology search of the NCBI database demonstrated that MakC2 and MakC3 are 
significantly similar to the members of cytochrome P450, some of which are involved in the 
stereo- and regio-specific oxidation of secondary metabolites. More detailed analysis of the 
amino acid sequences indicated that MakC2 and MakC3 have a highly conserved threonine in 
the I helix, which has been suggested to play a critical function in oxygen activation in most 
cytochromes P450 (Yoshigae et al. 2013) (Fig. 3.2a). Similarly, both MakC2 and MakC3 
possessed the well conserved K-helix ExxR motif (important to heme-binding and to stabilize 
protein conformation), and the heme-binding signature amino acid sequence FxxGxxxCxG, in 
which the cysteine residue serves as the fifth ligand to the heme iron (Werck-reichhart and 
Feyereisen 2000). These sequence characteristics suggested that both MakC2 and MakC3 can 
function as a cytochrome P450 monooxygenase. Moreover, phylogenetic analysis of MakC2 
and MakC3 with other cytochromes P450 from actinomycetes indicated that MakC2 belongs 
to the CYP105 family and MakC3 to the CYP107 family (Fig 3.2b). The CYP105 and CYP107 
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families are the most abundant of the streptomycete CYP families, and are associated with 
antibiotic biosynthetic pathways and xenobiotic degradation (Lamb et al. 2003), suggesting that 
MakC2 and/or MakC3 may have functions in the biosynthesis of maklamicin, although their 
actual roles cannot be adequately predicted by sequence alignment.  
 
Fig. 3.2. Sequence analysis of MakC2 and MakC3 with cytochromes P450 from actinomycetes. 
(a) Sequence alignment of the conserved domains between MakC2, MakC3 and cytochromes P450 involved 
in the biosynthesis of polyketide compounds. I, amino acid residues involved in oxygen activation; II, ExxR 
motif in the K-helix; III, signature sequence (FxxGxxxCxG) for the cytochrome P450 heme binding domain. 
Active sites in each domain are highlighted in black and light grey. Numbers indicate amino acid positions 
within each sequence. (b) Phylogenetic tree of MakC2, MakC3 and several cytochromes P450 from 
actinomycetes. Multiple sequence alignment was conducted with the CLUSTALW program. Phylogenetic 
trees were constructed by the unweighted-pair group method with the arithmetic mean 
(http://www.genome.jp/tools/clustalw/). CYP105, cytochrome P450 (CYP) 105 family; CYP107, CYP107 
family. The names and sequence accession numbers are shown in Appendix. 
 
3.3.2. Effect of disruptions of makC2 and makC3 on maklamicin production  
To investigate the roles of makC2 and makC3 in the biosynthesis of maklamicin, we 
generated both a makC2 disruptant (ΔmakC2) and a makC3 disruptant (ΔmakC3) by replacing 
the respective genes with an oriT-aac(3)IV cassette using λRED-mediated PCR-targeted 
mutagenesis (Fig. 3.3). 
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Fig. 3.3. Disruption of the makC2 and makC3 genes in Micromonospora sp. NBRC 110955 and 
genetic complementation of the makC2 disruptant. (A and B) Schematic representation of the strategy for 
gene disruption of makC2 (a) and makC3 (b). The oriT sequence is the RK2 origin of transfer. The aac(3)IV 
and hyg genes confer resistance for apramycin and hygromycin, respectively. (c) PCR analysis to confirm 
gene-disruption of makC2 and its complementation. An internal fragment (1,001 bp) of the makC2 gene was 
detected by using the primer pair makC2-cFw/makC2-cRe (upper panel). With the primer pair makC2-
tFw/makC2-tRe, a fragment (I, 1,681 bp) containing an intact makC2 gene or a fragment (1,927 bp) 
containing the oriT-aac(3)IV cassette was amplified with PCR (lower panel). The hyg (753 bp) gene was 
amplified using the primer pair hyg-Fw/hyg-Re. (d) PCR analysis to confirm the gene-disruption of makC3. 
An internal fragment (939 bp) of the makC3 gene was detected by using the primer pair makC3-cFw/makC3-
cRe (upper panel). With the primer pair makC3-tFw/makC3-tRe, a fragment (II, 1,579 bp) containing an 
intact makC3 gene or a fragment (1,857 bp) containing the cassette was amplified with PCR (lower panel). 
 
Maklamicin produced in the wild-type strain was readily detectable at the retention time 
of 15.7 min (Fig. 3.4b), whereas the ΔmakC2 strain completely lost the maklamicin production 
with concomitant appearance of a new compound at the retention time of 24.7 min (Fig. 3.4c). 
On the other hand, the disruption of makC3 had no effect on the production of maklamicin (Fig. 
3.4d), indicating that makC3 is not involved in the biosynthesis of maklamicin. To confirm that 
the metabolic changes observed in the ΔmakC2 strain resulted solely from the makC2 disruption, 
we reintroduced the entire makC2 gene into the makC2 disruptant (Fig.3.3). Because a narrow 
intergenic region (37 bp) between makC2 and makR3 has no plausible promoter sequences for 
the expression of makC2, makC2 may form a bicistronic operon with makR3, the latter of which 
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encodes a putative regulator of the Streptomyces antibiotic regulatory protein (SARP) family 
(Wietzorrek and Bibb 1997). Thus, we constructed the plasmid pLT130, which harboured the 
makC2 gene under the control of the strong constitutive ermEp* promoter. Complementation 
of the makC2 disruptant with pLT130 (ΔmakC2/makC2) abolished peak at 24.7 minute and 
restored the production of maklamicin to the level in the wild-type strain (Fig. 3.4e). These 
results clearly indicated that makC2-encoded cytochrome P450 is essential for the biosynthesis 
of maklamicin. 
 
3.3.3. Isolation and structure elucidation of compound 2 from the makC2 disruptant  
As described above, the accumulated compound at fig. 3.4c corresponding to peak at 24.7 
in the ΔmakC2 strain may be an intermediate in the biosynthesis of maklamicin. Therefore, I 
purified the new compound from the ΔmakC2 strain and elucidated the structure. After 
purification, 5.3 mg of purified compound was obtained from 2 L of the culture broth. The 
molecular formula of compound (fig 3.4c) was deduced to be C32H44O5 by the HRFABMS 
analysis (positive mode) {m/z 509.3273 [M+H]+ (calculated exact mass for C32H45O5: 
509.6946)}, suggesting that this compound may be a maklamicin analogue lacking one oxygen 
atom. The UV spectrum of this compound detected in the HPLC/DAD analysis was also 
Fig. 3.4. HPLC analysis of 
metabolites produced by genetically 
modified strains of Micromonospora 
sp. NBRC 110955.  (a) Maklamicin, 
an authentic standard of maklamicin (b) 
WT, wild-type strain (c) ΔmakC2, 
makC2 disruptant (d) ΔmakC3, makC3 
disruptant (e) ΔmakC2/makC2, makC2-
complemented ΔmakC2 strain. mAU, 
milliabsorbance units at 254 nm. 
Maklamicin was detected at the 
retention time of 15.7 min.  
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identical to that of maklamicin. Subsequently, the structure of compound was established by 
the analyses of 1H and 13C NMR data, demonstrating that these NMR spectra were quite similar 
to those of maklamicin (Table 3.2). However, there were two important differences between the 
NMR data for this compound and maklamicin, one each involving C-20 and C-29. The chemical 
shift of the C-20 quaternary carbon of this compound was slightly upfield shifted to 133.2 ppm 
from that of 137.0 ppm for maklamicin. Notably, the functional group of C-29 was found to be 
a methyl (δC 21.9, δH 1.75), while maklamicin has a hydroxymethyl at the same position (δC 
65.0, δH 3.99, 4.34). Together with the detection of key HMBC correlations for the primary 
frame of maklamicin, strong HMBC correlations were observed from the C-29 methyl protons 
to carbons at C-19, C-20 and C-21 (Fig. 3.5). Based on these findings, together with the data of 
1H-1H COSY and HSQC correlation, I confirmed the structure of compound from fig 3.4c as 
29-deoxymaklamicin (Fig. 3.1). (See Appendix for the definition of abbreviations).  
 
 
Fig. 3.5. Key HMBC correlations (H→C) of 29-deoxymaklamicin. 
3.3.4. Biological activity of 29-deoxymaklamicin 
To characterize the biological activity of 29-deoxymaklamicin as a new maklamicin 
analogue, I evaluated anti-microbial activity against 7 kinds of microorganisms previously 
tested (Table 3.3) 
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Table 3.2. NMR spectroscopic data of 29-deoxymaklamicin and maklamicin in CDCl3 
Position 
29-Deoxymaklamicin   Maklamicinb 
C H mult (J in Hz) HMBCa   C H
1 167.0  - -  167.0 - 
2 107.3 - -  107.2 - 
3 201.8 - -  201.9 - 
4 50.6 - -  50.6 - 
5 42.2 1.48, dd (9.8, 10.7) 4, 7, 25  42.2 1.47 
6 23.1 1.231, m -  23.1 1.23 
  2.02, m -   2.00 
7 32.73 1.575, m 26  32.71 1.57 
  1.73, m 6, 8    1.73 
8 27.7 2.08, m -  27.7 2.08 
9 39.4 1.41, m 5, 8, 10   39.5 1.40 
  1.59, m 5   1.59 
10 32.71 2.01, m -  32.68 1.98 
11 130.4 5.38, d (10.0) 10  130.38 5.38 
12 125.0  5.45, ddd (10.0, 5.9, 2.4) 4, 10, 13  125.0 5.46 
13 40.9 2.83, dd (5.34, 5.34) 4, 5, 11, 12, 14, 15, 25  41.0 2.83 
14 39.8 1.85, m 4, 15, 16,   39.8 1.85 
15 144.1 5.50, ddd (15.4, 9.6, 2.0) 5, 13  144.4 5.49 
16 121.1 5.01, m (overlap) 14,17   120.7 5.01 
17 42.3 1.91, br d (14.3) 15, 16, 18, 23  42.0 1.93 
  2.38, dd (14.1, 11.6) 15, 16, 18, 28   2.37 
18 39.2 - -  39.1 - 
19 129.7 5.02, s 18, 21, 23, 29  130.41 5.22 
20 133.2 - -  137.0 - 
21 32.9 2.43, m (overlap) -  28.6 2.74 
22 29.6 1.76 (overlap) 21, 23, 30  31.2 1.72 
  2.32, dd (14.5, 7.5) 21, 30   2.36 
23 86.1 - -  86.1 - 
24 204.5 - -  204.3 - 
25 15.8 1.579, s 3, 4  15.8 1.57 
26 18.9 1.04 d (7.2) 7, 8, 9   18.9 1.03 
27 20.7 0.86, d (7.3) 13, 15   20.7 0.86 
28 23.7 1.22, s 19, 23  23.4 1.25 
29 21.9 1.75, s 19, 20, 21  65.0 3.99 
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Table 3.2. Continue 
 
Position 
29-Deoxymaklamicin   Maklamicinb 
C H mult (J in Hz) HMBCa   C H
30 41.3 1.65, dd (16.7, 10.9) 20, 21, 31, 32  41.6 1.67 
  1.83, dd (14.3, 11.6) 20, 21, 22, 32   1.80  
31 65.5 3.85, m 21  66.6 3.82  
32 24.6 1.226, d (6.12)c 30, 31   24.6 1.21 
 
a HMBC correlations are from proton(s) to the indicated carbon.  
b Data from Igarashi et al. (4) 
c J-coupling constant calculated from 1H-NMR measured in 600 MHz using CD3OH as a solvent. 
 
29-Deoxymaklamicin showed an anti-Gram-positive bacteria spectrum comparable to that 
of maklamicin. Interestingly, the activity against Staphylococcus aureus NBRC12732 was 1.6 
μg/mL as an MIC value, which was significantly lower than that of maklamicin (13 μg/mL). 
On the other hand, 29-deoxymaklamicin showed no activity against Gram-negative bacteria 
strain E. coli NIH-JC2 and yeast C. albicans NBRC1594, similar to maklamicin. These results 
suggested that the functional group at C-29 appears to be significant for exerting the activity 
against Staphylococcus aureus.  
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Table 3.3. Antimicrobial activity of 29-deoxymaklamicin and maklamicin 
    MIC (μg ml-1) 
Microorganisms   29-Deoxymaklamicin Maklamicina 
Micrococcus luteus ATCC9343  0.8 0.2 
Staphylococcus aureus NBRC12732  1.6 13 
Bacillus subtilis PCI219  3.1 1.7 
Bacillus cereus NBRC15305  6.3 6.5 
Enterococcus faecalis NBRC100480  6.3 13 
Candida albicans NBRC1594  >100 50 
Escherichia coli NIH-JC2   >100 >50 
a Data from Igarashi et al.  
 
3.3.5. Bioconversion of 29-deoxymaklamicin to maklamicin in recombinant S. avermitilis 
expressing makC2  
According to the structure of 29-deoxymaklamicin, I assumed that makC2 gene might 
function as the hydroxylase in maklamicin biosynthesis. Therefore, to confirm that MakC2 
catalyses specific hydroxylation at C-29 in vivo, I performed a bioconversion study using S. 
avermitilis SUKA22 carrying the plasmid pLT130, which was used for genetic 
complementation of the makC2 disruptant. The bioconversion using 29-deoxymaklamicin as 
the substrate with the recombinant S. avermitilis strain, in which heterologous expression of 
makC2 was successfully achieved (Fig. 3.6), demonstrated that 29-deoxymaklamicin was 
converted to maklamicin (retention time of 16.3 min) (Fig. 3.7), while no such conversion was 
observed without 29-deoxymaklamicin. The UV-visible spectrum of the newly appeared peak 
exhibited the same maximum UV absorption as maklamicin (Fig. 3.8). In contrast, the parental 
S. avermitilis strain incubated with 29-deoxymaklamicin showed no conversion, indicating the 
makC2-dependent conversion to maklamicin. These results strongly indicated that MakC2 is 
the regio-specific hydroxylase converting 29-deoxymaklamicin into maklamicin in vivo, as a 
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last tailoring step of the maklamicin biosynthetic pathway.  
 
 
Fig. 3.6. Heterologous expression of makC2 in S. avermitilis SUKA22. Transcription of the 
introduced makC2 gene was measured by semiquantitative RT-PCR. The expression of makC2 was examined 
in the S. avermitilis SUKA22 harbouring pLT130 (left lane) or no plasmid (right lane). The hrdB-like gene 
[hrdB encodes the major sigma factor in Streptomyces coelicolor A3(2)] was used as a control.  
 
 
Fig. 3.7. Bioconversion of 29-deoxymaklamicin by recombinant S. avermitilis strains.  (a) HPLC 
chromatograms of crude extracts in the resting cell reaction are shown. (b) The enlargement of HPLC 
chromatogram of (a) from 14 to 22 min. (i) Culture extract of Micromonospora sp. NBRC 110955; (ii) 
purified 29-deoxymaklamicin used as a standard; (iii) S. avermitilis harbouring makC2 incubated with 29-
deoxymaklamicin; (iv) S. avermitilis harbouring makC2 incubated with MeOH; (iv) S. avermitilis incubated 
with 29-deoxymaklamicin. Authentic maklamicin and 29-deoxymaklamicin were detected at the retention 
times of 16.3 (filled inverted triangle) and 25.6 min (open inverted triangle), respectively. 
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Fig. 3.8. The UV-visible spectrum of the peak appeared after incubation of 
S. avermitilis harboring makC2 with 29- deoxymaklamicin. The symbols 
are identical to those indicated in Fig. 3.7; filled inverted triangle, peak at 
16.3 min in panel i); filled circle, peak at 16.3 min in panel iii); filled 
diamond, peak at 16.3 min in panel v).  
 
 
 
 
 
 
 
 
3.4. Discussion 
The biosynthetic mechanism of the spirotetronate-class antibiotics has been shown to 
include a polyketide assembly line, a glycerate utilization system, a sugar modification, and a 
novel [4+2]-cycloaddition system for the spirotetronate skeleton (Hashimoto et al. 2015; Tian 
et al. 2015; Vieweg et al. 2014). However, there has been no report on systems for the 
modification of peripheral moieties on the main skeletons of these compounds. I recently 
identified the mak gene cluster and, based on this information, proposed a biosynthetic pathway 
for maklamicin. I have shown here that MakC2, a probable cytochrome P450 monooxygenase, 
catalyses a region-specific hydroxylation at the C-29 methyl group of 29-deoxymaklamicin via 
gene inactivation, structural elucidation of 29-deoxymaklamicin, and resting cell conversion. 
In contrast, MakC3, another cytochrome P450 in the mak cluster, is not involved in this 
biosynthetic process, and appears to be responsible for the production of another, as yet 
unidentified, previously proposed polyketide compound. The biosynthetic gene clusters of 
kijanimicin, versipelostatin, lobophorin, and chlorothricin (Hashimoto et al. 2015; Jia et al. 
2006; Li et al. 2013; Zhang et al. 2007), all of which are spirotetronates containing the trans-
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decalin moiety, are also found to have cytochrome P450 genes such as kijA3, vstD, lobP1, and 
chlE2, respectively. These genes have been proposed to be responsible for introducing a 
hydroxy group on each of their own core structures (kijA3 for C-20 of kijanimicin, vstD for C-
37 of versipelostatin, and lobP1 for C-32 of lobophorin) or the oxidation of a methyl group to 
form a carboxy group (chlE2 for C-20 of chlorothricin), without any functional characterization. 
Therefore, this work represents the first functional analysis of cytochrome P450 genes 
embedded in the biosynthetic gene cluster of spirotetronate antibiotics, and could provide 
information useful for deciphering tailoring steps in the biosynthesis of these spirotetronate 
antibiotics.  
With respect to biological activity, 29-deoxymaklamicin showed an antimicrobial 
spectrum similar to that of maklamicin: both of them exhibited strong-to-modest anti-Gram-
positive activities and no activity against Gram-negative bacteria and yeast. It is interesting that 
the lack of a C-29 hydroxy group in 29-deoxymaklamicin enhanced the activity to 
Staphylococcus aureus. Jia et al. (Jia et al. 2006) demonstrated that demethylsalicycloyl 
chlorothricin synthesized by a genetically engineered strain of the chlorothricin producer 
showed decreased biological activity in comparison to that of chlorothricin. However, little 
information is currently available on the degree to which the level of post-PKS modifications 
may affect the biological activity of spirotetronate antibiotics. Thus, 29-deoxymaklamicin and 
the cognate hydroxylase MakC2 would be useful for analysing the mode of action underlying 
the anti-Gram-positive activity of not only maklamicin, but also the spirotetronate antibiotics. 
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3.5. Summary 
In this chapter, I characterized the function of cytochrome P450 encoded by makC2 and 
makC3 by gene inactivation. Gene deletion of makC2 resulted in the complete loss maklamicin 
production and then created a new maklamicin analogue [29-deoxymaklamicin]. In contrast, 
gene deletion of makC3 did not affect the maklamicin production. 29-Deoxymaklamicin 
showed strong-to-modest anti-microbial activity against Gram-positive bacteria notably the 
activity against Staphylococcus aureus. Moreover, the bioconversion of 29-deoxymaklamicin 
into maklamicin by resting cell assay confirmed that MakC2 is the final-step hydroxylase in the 
formation of mature maklamicin.   
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Chapter 4 
 
General conclusions 
 
Actinomycetes are Gram-positive, filamentous and high-GC-content bacteria that display 
two typical features. The first is the complex life cycle of morphological differentiation, and 
the second is the ability to produce numerous types of secondary metabolites. Approximately 
two-thirds of the important antibiotics produced by actimomycetes are produced by the bacteria 
in the genus Streptomyces. However, non-Streptomyces actinomycetes (rare actinomycetes) are 
also promising sources of secondary metabolites and have attracted interest from the viewpoint 
of providing novel natural products. 
A significant genus of the rare-actinomycetes group is Micromonospora. This genus 
displays a complex life cycle, differentiating into both substrate mycelia and spores, but no 
aerial mycelia are produced. Micromonospora species are prolific sources of various bioactive 
metabolites, second only to Streptomyces. The Micromonospora strains are well known for 
producing antibiotics, especially aminoglycosides, enediynes and oligosaccharides. 
Secondary metabolites are compounds that are mostly low-molecular-weight but 
chemically diverse compounds. Secondary metabolites can be divided into several groups, and 
one of the major groups of secondary metabolites is polyketide compounds. Polyketides exhibit 
an incredible range of functional and structural diversity with significant activities including 
antibacterial, anticancer, antifungal, antiparasitic and immunosuppressive properties. 
Polyketides are produced by polyketide synthases (PKSs) by Claisen condensation of acyl-CoA 
precursors to generate -ketoacyl, and then further modified by different reduction activities 
such as those of ketoreductase, dehydratase and enoly-reductase. 
After the polyketide scaffold has been synthesized, post-PKS tailoring modification is an 
important step that changes the polyketide core structure. Modifications such as the introduction 
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of a hydroxyl group or methyl group or glycosyl transfer are essential for altering the biological 
activities of these groups of natural products. 
Spirotetronates are polyketide-class compounds possessing an unusual structure 
composed of a tetronic acid moiety spiro-linked with a cyclohexene ring, sometimes conjugated 
to a trans-decalin unit. The compounds in this class exhibit a broad range of molecular targets 
and biological (e.g., antimicrobial, antitumor, antiviral and cholesterol biosynthesis-inhibiting) 
activities. To date, nearly 60 related compounds in the spirotetronate family have been reported, 
and their structural diversity was shown to be derived mostly from the glycosylation pattern 
and the length of the carbon chain connecting the decalin unit and cyclohexene ring. 
Based on the size of its ring system and its molecular weight, maklamicin was classified 
as a small spirotetronate compound, consisting of an 11-member system. Among the nearly 60 
known compounds, maklamicin has two structural features that are unique from those of other 
spirotetronates. (1) The four-carbon chain linker of maklamicin is the shortest in this family. (2) 
The presence of a 2R-hydroxy-propyl group at C-21, which creates the stereogenic center at C-
31 on the cyclohexene ring, has not been reported. Based on the structural uniqueness of 
maklamicin in the family of spirotetronate antibiotics, I then attempted to elucidate the 
biosynthetic mechanism of maklamicin at the molecular level. 
This thesis is divided into four chapters, organized as follows. The basic knowledge 
related to my study is given in Chapter 1, with a general introduction describing Actinomycetes, 
the genus Micromonospora, secondary metabolites, and the classification of compounds based 
on their core component, with a focus on polyketide compounds. The known information about 
polyketide compounds and polyketide synthases together with detailed findings regarding 
tetronate and spirotetronate compounds are summarized in this chapter. 
 
In Chapter 2, I report the identification and characterization of the biosynthetic (mak) gene 
cluster in maklamicin. To increase our understanding of the structural uniqueness of 
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maklamicin, I sought to elucidate the maklamicin biosynthetic gene cluster through genome 
sequencing and library screening. The sequence analysis revealed that a plausible maklamicin 
cluster covers a 152-kb DNA region encoding 46 open reading frames (ORFs). Twenty-four 
genes can be assigned roles in the biosynthesis of maklamicin, including a polyketide backbone, 
spirotetronate and peripheral moieties, self-resistance, and the regulation of maklamicin 
production. Disruption of the PKS genes, resulting in a complete loss of maklamicin production, 
indicated that a type I modular PKS system is responsible for the biosynthesis of maklamicin. 
Moreover, the mak gene cluster contained a set of biosynthetic genes for the formation of a 
tetronate moiety, and these genes were found to be highly conserved in the gene clusters for 
spirotetronate. Subsequently, I propose a hypothesis regarding the biosynthesis of maklamicin 
based on the estimated gene cluster. In this proposed biosynthesis, the inactivation of the 
dehydratase (DH) domain at the initial module in the PKS assembly line causes the structural 
variation in maklamicin, which makes maklamicin unique from other spirotetronates. 
 
Chapter 3 describes my investigation of the function of the genes involved in the post-
PKS modification of maklamicin biosynthesis. One tailoring step in the biosynthesis is 
predicted to be post-PKS modification, which appears to be catalyzed by the putative 
cytochrome P450 monooxygenases MakC2 and/or MakC3. The gene disruption of makC2 
resulted in the complete loss of maklamicin production with a simultaneous accumulation of a 
new compound (29-deoxymaklamicin), whereas the gene disruption of makC3 did not affect 
the maklamicin production. The structure of 29-deoxymaklamicin, which was obtained from a 
makC2 disruption strain, shows the presence of a methyl group at C-29 instead of a hydroxy 
group in maklamicin. Moreover, the bioconversion of 29-deoxymaklamicin to maklamicin in 
recombinant Streptomyces avermitilis SUKA22 indicated that MakC2 is a post-PKS 
modification enzyme, responsible for hydroxylation in maklamicin biosynthesis. This 
information suggested that 29-deoxymaklamicin is an intermediate in the biosynthetic pathway 
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of maklamicin and would serve as the substrate of maklamicin. Additionally, 29-
deoxymaklamicin displayed antibacterial activity against Gram-positive bacteria, with 
enhanced activity against Staphylococcus aureus. These results imply that altering the post-
PKS tailoring pathway can be an alternative way to generate compounds with different 
biological activities. 
 
In this study, the biosynthetic gene cluster of maklamicin, a spirotetronate-class 
polyketide antibiotic, was identified from the endophytic Micromonospora sp. NBRC 110955. 
Based on the maklamicin gene cluster, I was able to gain more insight into the biosynthesis of 
spirotetronate compounds and to increase our understanding of the detailed mechanisms 
underlying the structural changes in maklamicin. This understanding could be applied in other 
spirotetronates that feature the same structural variation. The information about the maklamicin 
gene cluster could contribute to the creation of new maklamicin analogues. 
In addition, this study is the first report of the genetic inactivation of cytochrome P450 in 
the spirotetronate family, and I expect that the genetic engineering of this inactive cytochrome 
P450 will open the way to the creation of more spirotetronates with structural diversity and 
significantly improved properties. Lastly, my comparative analysis of the maklamicin gene 
cluster with those of other spirotetronates provides information about conserved genes that 
could be useful in genome mining and screening for the rapid identification of actinobacteria 
that produce new spirotetronates. 
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Appendix 1 
 
The protein names and sequence accession number  
 
Protein name Accession number Source 
ChlA1 AAZ77693 Streptomyces antibioticus 
ChlA3 AAZ77696 Streptomyces antibioticus 
ChlA5 AAZ77698 Streptomyces antibioticus 
ChlE2 AAZ77695 Streptomyces antibioticus 
PyrE2 AFV71331 Streptomyces rugosporus NRRL 21084 
PtmO5 ACO31280 Streptomyces platensis MA7327 
AmphN AAK73509 Streptomyces nodosus 
NysN AAF71771 Streptomyces noursei ATCC 11455 
RimG AAR16519 Streptomyces diastaticus 108 
ScnG ADX66468 Streptomyces chattanoogenesis L10 
NikF CAB46536 Streptomyces tandae Tue901 
TylHI AAD12167 Streptomyces fradiae 
TamI ADC79647 Streptomyces sp. 307-9 
SlgO2 CBA11565 Streptomyces lydicus NRRL 2433 
AJAP_10910 AIG75072 Amycolatopsis japonica  
RubU AAM97370 Streptomyces collinus DSM2012 
PikC AAC68886 Streptomyces venezuelae ATCC15439 
DF18_18885 KEF19452 Streptomyces rimosus 
SFRA_14170 KDS87380 Streptomyces fradiae ATCC 19609 
SIRAN2716 CDR05783 Streptomyces iranensis  
EryF AAA26496 Saccharopolyspora erythraea NRRL 2338 
RapN CAA60465 Streptomyces rapamycinicus NRRL 5491 
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Appendix 2 
 
The table shows the definition of abbreviations from chapter 3  
 
Abbreviations Definition 
HPLC-DAD High-Performance Liquid Chromatography with Diode 
Array Detection 
HRFABMS High Resolution Fast Atom Bombardment Mass 
Spectrometry 
NMR Nuclear Magnetic Resonance 
HMBC Heteronuclear Multi-Bond Correlation 
UV-Vis spectrum Ultraviolet-Visible spectrum 
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